Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssspta1626amd

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

```
 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2  Apr 08  "Ask CAS" for self-help around the clock
 NEWS  3  Apr 09  BEILSTEIN: Reload and Implementation of a New Subject Area
 NEWS  4  Apr 09  ZDB will be removed from STN
 NEWS  5  Apr 19  US Patent Applications available in IFICDB, IFIPAT, and
IFIUDB
 NEWS  6  Apr 22  Records from IP.com available in CAPLUS, HCAPLUS, and
ZCAPLUS
 NEWS  7  Apr 22  BIOSIS Gene Names now available in TOXCENTER
 NEWS  8  Apr 22  Federal Research in Progress (FEDRIP) now available
 NEWS  9  Jun 03  New e-mail delivery for search results now available
 NEWS 10  Jun 10  MEDLINE Reload
 NEWS 11  Jun 10  PCTFULL has been reloaded
 NEWS 12  Jul 02  FOREGE no longer contains STANDARDS file segment
 NEWS 13  Jul 22  USAN to be reloaded July 28, 2002;
                  saved answer sets no longer valid
 NEWS 14  Jul 29  Enhanced polymer searching in REGISTRY
 NEWS 15  Jul 30  NETFIRST to be removed from STN
 NEWS 16  Aug 08  CANCERLIT reload
 NEWS 17  Aug 08  PHARMAMarketLetter(PHARMAML) - new on STN
 NEWS 18  Aug 08  NTIS has been reloaded and enhanced
 NEWS 19  Aug 19  Aquatic Toxicity Information Retrieval (AQUIRE)
                  now available on STN
 NEWS 20  Aug 19  IFIPAT, IFICDB, and IFIUDB have been reloaded
 NEWS 21  Aug 19  The MEDLINE file segment of TOXCENTER has been reloaded
 NEWS 22  Aug 26  Sequence searching in REGISTRY enhanced
 NEWS 23  Sep 03  JAPIO has been reloaded and enhanced
 NEWS 24  Sep 16  Experimental properties added to the REGISTRY file
 NEWS 25  Sep 16  CA Section Thesaurus available in CAPLUS and CA
 NEWS 26  Oct 01  CASREACT Enriched with Reactions from 1907 to 1985
 NEWS 27  Oct 21  EVENTLINE has been reloaded
 NEWS 28  Oct 24  BEILSTEIN adds new search fields
 NEWS 29  Oct 24  Nutraceuticals International (NUTRACEUT) now available on
STN
 NEWS 30  Oct 25  MEDLINE SDI run of October 8, 2002
 NEWS 31  Nov 18  DKILIT has been renamed APOLLIT
 NEWS 32  Nov 25  More calculated properties added to REGISTRY
 NEWS 33  Dec 02  TIBKAT will be removed from STN
 NEWS 34  Dec 04  CSA files on STN
 NEWS 35  Dec 17  PCTFULL now covers WP/PCT Applications from 1978 to date
 NEWS 36  Dec 17  TOXCENTER enhanced with additional content
 NEWS 37  Dec 17  Adis Clinical Trials Insight now available on STN
 NEWS 38  Dec 30  ISMEC no longer available
```

```
NEWS 39   Jan 21  NUTRACEUT offering one free connect hour in February 2003
NEWS 40   Jan 21  PHARMAML offering one free connect hour in February 2003
NEWS 41   Jan 29  Simultaneous left and right truncation added to COMPENDEX,
                  ENERGY, INSPEC
NEWS 42   Feb 13  CANCERLIT is no longer being updated
NEWS 43   Feb 24  METADEX enhancements
NEWS 44   Feb 24  PCTGEN now available on STN
NEWS 45   Feb 24  TEMA now available on STN
NEWS 46   Feb 26  NTIS now allows simultaneous left and right truncation
NEWS 47   Feb 26  PCTFULL now contains images
NEWS 48   Mar 04  SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 49   Mar 19  APOLLIT offering free connect time in April 2003
NEWS 50   Mar 20  EVENTLINE will be removed from STN
NEWS 51   Mar 24  PATDPAFULL now available on STN
NEWS 52   Mar 24  Additional information for trade-named substances without
                  structures available in REGISTRY
NEWS 53   Mar 24  Indexing from 1957 to 1966 added to records in CA/CAPLUS

NEWS EXPRESS  January 6 CURRENT WINDOWS VERSION IS V6.01a,
              CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
              AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS    STN Operating Hours Plus Help Desk Availability
NEWS INTER    General Internet Information
NEWS LOGIN    Welcome Banner and News Items
NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *



FILE 'HOME' ENTERED AT 12:48:38 ON 02 APR 2003

=> fil reg
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                 0.21       0.21

FILE 'REGISTRY' ENTERED AT 12:48:43 ON 02 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    1 APR 2003  HIGHEST RN 501325-53-7
DICTIONARY FILE UPDATES:   1 APR 2003  HIGHEST RN 501325-53-7
```

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 09980452.str

L1   STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1   STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 ful
FULL SEARCH INITIATED 12:49:01 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 45478 TO ITERATE

100.0% PROCESSED 45478 ITERATIONS 34 ANSWERS
SEARCH TIME: 00.00.01

L2 34 SEA SSS FUL L1

=> s l2 and caplus/lc
27100399 CAPLUS/LC
L3 15 L2 AND CAPLUS/LC

=> s l2 not l3
L4 19 L2 NOT L3

=> d 1-19

L4 ANSWER 1 OF 19 REGISTRY COPYRIGHT 2003 ACS
RN 438455-95-9 REGISTRY
CN 9H-Xanthene-9-carboxamide, N-[3-(1H-imidazol-1-yl)propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C20 H19 N3 O2
SR Chemical Library
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 ANSWER 2 OF 19 REGISTRY COPYRIGHT 2003 ACS
RN 438022-05-0 REGISTRY
CN 2H-1-Benzopyran-3-carboxamide, N-[3-(1H-imidazol-1-yl)propyl]-2-oxo- (9CI)
(CA INDEX NAME)
FS 3D CONCORD
MF C16 H15 N3 O3
SR Chemical Library
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 ANSWER 3 OF 19 REGISTRY COPYRIGHT 2003 ACS
RN 377767-99-2 REGISTRY
CN 4H-1-Benzopyran-2-carboxamide, N-[3-(1H-imidazol-1-yl)propyl]-4-oxo- (9CI)
(CA INDEX NAME)
FS 3D CONCORD
MF C16 H15 N3 O3
SR Chemical Library
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 ANSWER 4 OF 19 REGISTRY COPYRIGHT 2003 ACS
RN 342384-05-8 REGISTRY
CN 3H-Naphtho[2,1-b]pyran-2-carboxamide, N-[3-(1H-imidazol-1-yl)propyl]-3-oxo- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C20 H17 N3 O3
SR Chemical Library
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 ANSWER 5 OF 19 REGISTRY COPYRIGHT 2003 ACS
RN 326612-92-4 REGISTRY
CN 2H-1-Benzopyran-3-carboxamide, N-[3-(1H-imidazol-1-yl)propyl]-6-methoxy-2-oxo- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C17 H17 N3 O4
SR Chemical Library
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 ANSWER 6 OF 19 REGISTRY COPYRIGHT 2003 ACS
RN 320761-58-8 REGISTRY
CN 2H-1-Benzopyran-3-carboxamide, 6-bromo-N-[[3-(3-hydroxyphenyl)-1,2,4-oxadiazol-5-yl]methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2-oxo- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H20 Br N5 O5
SR Chemical Library



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 ANSWER 7 OF 19 REGISTRY COPYRIGHT 2003 ACS
RN 320757-46-8 REGISTRY
CN 2H-1-Benzopyran-3-carboxamide, 6-bromo-N-[[3-(4'-hydroxy[1,1'-biphenyl]-4-yl)-1,2,4-oxadiazol-5-yl]methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2-oxo- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C31 H24 Br N5 O5
SR Chemical Library
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 ANSWER 8 OF 19 REGISTRY COPYRIGHT 2003 ACS
RN 320732-57-8 REGISTRY
CN 2H-1-Benzopyran-3-carboxamide, N-[[3-(4'-hydroxy[1,1'-biphenyl]-4-yl)-1,2,4-oxadiazol-5-yl]methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2-oxo- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C31 H25 N5 O5
SR Chemical Library
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 ANSWER 9 OF 19 REGISTRY COPYRIGHT 2003 ACS
RN 320623-00-5 REGISTRY
CN 4H-1-Benzopyran-2-carboxamide,
N-[[3-(4'-hydroxy[1,1'-biphenyl]-4-yl)-

1,2,4-oxadiazol-5-yl]methyl]-N-[3-(1H-imidazol-1-yl)propyl]-6-methyl-4-oxo
-
(9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C32 H27 N5 O5
SR Chemical Library



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 ANSWER 10 OF 19 REGISTRY COPYRIGHT 2003 ACS
RN 320622-83-1 REGISTRY
CN 2H-1-Benzopyran-3-carboxamide,
N-[[3-(3-hydroxyphenyl)-1,2,4-oxadiazol-5-
yl]methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2-oxo- (9CI) (CA INDEX
NAME)
FS 3D CONCORD
MF C25 H21 N5 O5
SR Chemical Library



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 ANSWER 11 OF 19 REGISTRY COPYRIGHT 2003 ACS
RN 320605-10-5 REGISTRY
CN 2H-1-Benzopyran-3-carboxamide, 6-bromo-N-[[3-(4-hydroxyphenyl)-1,2,4-
oxadiazol-5-yl]methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2-oxo- (9CI)
(CA
INDEX NAME)
FS 3D CONCORD
MF C25 H20 Br N5 O5
SR Chemical Library



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 ANSWER 12 OF 19 REGISTRY COPYRIGHT 2003 ACS
RN 318993-37-2 REGISTRY
CN 2H-1-Benzopyran-3-carboxamide,
N-[[3-(4-hydroxyphenyl)-1,2,4-oxadiazol-5-
yl]methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2-oxo- (9CI) (CA INDEX
NAME)
FS 3D CONCORD
MF C25 H21 N5 O5
SR Chemical Library
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 ANSWER 13 OF 19 REGISTRY COPYRIGHT 2003 ACS
RN 318993-32-7 REGISTRY
CN 4H-1-Benzopyran-2-carboxamide,
N-[[3-(4-hydroxyphenyl)-1,2,4-oxadiazol-5-
yl]methyl]-N-[3-(1H-imidazol-1-yl)propyl]-6-methyl-4-oxo- (9CI) (CA
INDEX
NAME)
FS 3D CONCORD
MF C26 H23 N5 O5
SR Chemical Library
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 ANSWER 14 OF 19 REGISTRY COPYRIGHT 2003 ACS
RN 318991-68-3 REGISTRY
CN 4H-1-Benzopyran-2-carboxamide,
N-[[3-(3-hydroxyphenyl)-1,2,4-oxadiazol-5-
yl]methyl]-N-[3-(1H-imidazol-1-yl)propyl]-6-methyl-4-oxo- (9CI) (CA
INDEX
NAME)
FS 3D CONCORD
MF C26 H23 N5 O5
SR Chemical Library
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 ANSWER 15 OF 19 REGISTRY COPYRIGHT 2003 ACS
RN 318991-35-4 REGISTRY
CN 2H-1-Benzopyran-3-carboxamide,
N-{[3-(2-fluoro-4-hydroxyphenyl)-1,2,4-
oxadiazol-5-yl]methyl}-N-[3-(1H-imidazol-1-yl)propyl]-2-oxo- (9CI)
(CA
INDEX NAME)
FS 3D CONCORD
MF C25 H20 F N5 O5
SR Chemical Library
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 ANSWER 16 OF 19 REGISTRY COPYRIGHT 2003 ACS
RN 318991-28-5 REGISTRY
CN 4H-1-Benzopyran-2-carboxamide, N-[[3-(2-fluoro-4-hydroxyphenyl)-1,2,4-
oxadiazol-5-yl]methyl]-N-[3-(1H-imidazol-1-yl)propyl]-6-methyl-4-oxo-
(9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C26 H22 F N5 O5
SR Chemical Library
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 ANSWER 17 OF 19 REGISTRY COPYRIGHT 2003 ACS
RN 318991-26-3 REGISTRY
CN 2H-1-Benzopyran-3-carboxamide,
6-bromo-N-[(3-(2-fluoro-4-hydroxyphenyl)-
1,2,4-oxadiazol-5-yl]methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2-oxo-
(9CI)
(CA INDEX NAME)
FS 3D CONCORD
MF C25 H19 Br F N5 O5
SR Chemical Library
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 ANSWER 18 OF 19 REGISTRY COPYRIGHT 2003 ACS
RN 227466-87-7 REGISTRY
CN 2-Imidazolidinone,
1-[3-[[(2R)-2-[(2S)-3,4-dihydro-2H-1-benzopyran-2-yl]-2-
hydroxyethyl]amino]propyl]-, rel- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C17 H25 N3 O3
CI COM
SR CA

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 ANSWER 19 OF 19 REGISTRY COPYRIGHT 2003 ACS
RN 227297-11-2 REGISTRY
CN 2-Imidazolidinone, 1-[3-[[[(2R)-3,4-dihydro-2H-1-benzopyran-2-
yl]methyl]amino]propyl]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C16 H23 N3 O2
CI COM
SR CA

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

=>
Uploading 09980452.str

L5 STRUCTURE UPLOADED

=> d
L5 HAS NO ANSWERS
L5 STR





Structure attributes must be viewed using STN Express query preparation.

=> s l5 ful
FULL SEARCH INITIATED 12:50:55 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 50136 TO ITERATE

100.0% PROCESSED 50136 ITERATIONS 6797 ANSWERS
SEARCH TIME: 00.00.01

L6 6797 SEA SSS FUL L5

=>
Uploading 09980452.str

L7 STRUCTURE UPLOADED

=> d
L7 HAS NO ANSWERS
L7 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l7 ful
FULL SEARCH INITIATED 12:54:59 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 49555 TO ITERATE

100.0% PROCESSED 49555 ITERATIONS 137 ANSWERS
SEARCH TIME: 00.00.01

L8 137 SEA SSS FUL L7

=> s l8 and caplus/lc

```
      27100399 CAPLUS/LC
L9          114 L8 AND CAPLUS/LC

=> s l8 not l9
L10          23 L8 NOT L9

=> d 1-23
```

L10 ANSWER 1 OF 23 REGISTRY COPYRIGHT 2003 ACS
RN 438455-95-9 REGISTRY
CN 9H-Xanthene-9-carboxamide, N-[3-(1H-imidazol-1-yl)propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C20 H19 N3 O2
SR Chemical Library
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L10 ANSWER 2 OF 23 REGISTRY COPYRIGHT 2003 ACS
RN 438022-05-0 REGISTRY
CN 2H-1-Benzopyran-3-carboxamide, N-[3-(1H-imidazol-1-yl)propyl]-2-oxo- (9CI)
(CA INDEX NAME)
FS 3D CONCORD
MF C16 H15 N3 O3
SR Chemical Library
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L10 ANSWER 3 OF 23 REGISTRY COPYRIGHT 2003 ACS
RN 377767-99-2 REGISTRY
CN 4H-1-Benzopyran-2-carboxamide, N-[3-(1H-imidazol-1-yl)propyl]-4-oxo- (9CI)
(CA INDEX NAME)
FS 3D CONCORD
MF C16 H15 N3 O3
SR Chemical Library
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L10 ANSWER 4 OF 23 REGISTRY COPYRIGHT 2003 ACS
RN 361209-82-7 REGISTRY
CN 3-Pyridinecarboxamide, N-[3-(1H-imidazol-1-yl)propyl]-6-[4-[(4-oxo-4H-1-benzopyran-2-yl)carbonyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C26 H26 N6 O4
SR Chemical Library
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L10 ANSWER 5 OF 23 REGISTRY COPYRIGHT 2003 ACS
RN 342384-05-8 REGISTRY
CN 3H-Naphtho[2,1-b]pyran-2-carboxamide,
N-[3-(1H-imidazol-1-yl)propyl]-3-oxo-
(9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C20 H17 N3 O3
SR Chemical Library
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L10 ANSWER 6 OF 23 REGISTRY COPYRIGHT 2003 ACS
RN 326612-92-4 REGISTRY
CN 2H-1-Benzopyran-3-carboxamide,
N-[3-(1H-imidazol-1-yl)propyl]-6-methoxy-2-
oxo- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C17 H17 N3 O4
SR Chemical Library
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L10 ANSWER 7 OF 23 REGISTRY COPYRIGHT 2003 ACS
RN 320761-58-8 REGISTRY
CN 2H-1-Benzopyran-3-carboxamide, 6-bromo-N-[[3-(3-hydroxyphenyl)-1,2,4-
oxadiazol-5-yl]methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2-oxo- (9CI)
(CA
INDEX NAME)
FS 3D CONCORD
MF C25 H20 Br N5 O5
SR Chemical Library



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L10 ANSWER 8 OF 23 REGISTRY COPYRIGHT 2003 ACS
RN 320757-46-8 REGISTRY
CN 2H-1-Benzopyran-3-carboxamide,
6-bromo-N-[[3-(4'-hydroxy[1,1'-biphenyl]-4-
yl)-1,2,4-oxadiazol-5-yl]methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2-oxo-
(9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C31 H24 Br N5 O5
SR Chemical Library
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L10 ANSWER 9 OF 23 REGISTRY COPYRIGHT 2003 ACS
RN 320732-57-8 REGISTRY
CN 2H-1-Benzopyran-3-carboxamide,
N-{[3-(4'-hydroxy[1,1'-biphenyl]-4-yl)-
1,2,4-oxadiazol-5-yl]methyl}-N-[3-(1H-imidazol-1-yl)propyl]-2-oxo-
(9CI)
(CA INDEX NAME)
FS 3D CONCORD
MF C31 H25 N5 O5
SR Chemical Library
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L10 ANSWER 10 OF 23 REGISTRY COPYRIGHT 2003 ACS
RN 320623-00-5 REGISTRY
CN 4H-1-Benzopyran-2-carboxamide, N-[[3-(4'-hydroxy[1,1'-biphenyl]-4-yl)-
1,2,4-oxadiazol-5-yl]methyl]-N-[3-(1H-imidazol-1-yl)propyl]-6-methyl-4-oxo-
(9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C32 H27 N5 O5
SR Chemical Library



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L10 ANSWER 11 OF 23 REGISTRY COPYRIGHT 2003 ACS
RN 320622-83-1 REGISTRY
CN 2H-1-Benzopyran-3-carboxamide,
N-[[3-(3-hydroxyphenyl)-1,2,4-oxadiazol-5-
yl]methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2-oxo- (9CI) (CA INDEX
NAME)
FS 3D CONCORD
MF C25 H21 N5 O5
SR Chemical Library



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L10 ANSWER 12 OF 23 REGISTRY COPYRIGHT 2003 ACS
RN 320605-10-5 REGISTRY
CN 2H-1-Benzopyran-3-carboxamide, 6-bromo-N-[[3-(4-hydroxyphenyl)-1,2,4-
oxadiazol-5-yl]methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2-oxo- (9CI)
(CA
INDEX NAME)
FS 3D CONCORD
MF C25 H20 Br N5 O5
SR Chemical Library



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L10 ANSWER 13 OF 23 REGISTRY COPYRIGHT 2003 ACS
RN 318993-37-2 REGISTRY
CN 2H-1-Benzopyran-3-carboxamide,
N-[[3-(4-hydroxyphenyl)-1,2,4-oxadiazol-5-
yl]methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2-oxo- (9CI) (CA INDEX
NAME)
FS 3D CONCORD
MF C25 H21 N5 O5
SR Chemical Library
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L10 ANSWER 14 OF 23 REGISTRY COPYRIGHT 2003 ACS
RN 318993-32-7 REGISTRY
CN 4H-1-Benzopyran-2-carboxamide,
N-[[3-(4-hydroxyphenyl)-1,2,4-oxadiazol-5-
yl]methyl]-N-[3-(1H-imidazol-1-yl)propyl]-6-methyl-4-oxo- (9CI) (CA
INDEX
NAME)
FS 3D CONCORD
MF C26 H23 N5 O5
SR Chemical Library
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L10 ANSWER 15 OF 23 REGISTRY COPYRIGHT 2003 ACS
RN 318991-68-3 REGISTRY
CN 4H-1-Benzopyran-2-carboxamide,
N-[[3-(3-hydroxyphenyl)-1,2,4-oxadiazol-5-
yl]methyl]-N-[3-(1H-imidazol-1-yl)propyl]-6-methyl-4-oxo- (9CI) (CA
INDEX
NAME)
FS 3D CONCORD
MF C26 H23 N5 O5
SR Chemical Library
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L10 ANSWER 16 OF 23 REGISTRY COPYRIGHT 2003 ACS
RN 318991-35-4 REGISTRY
CN 2H-1-Benzopyran-3-carboxamide, N-[[3-(2-fluoro-4-hydroxyphenyl)-1,2,4-
oxadiazol-5-yl]methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2-oxo- (9CI)
(CA
INDEX NAME)
FS 3D CONCORD
MF C25 H20 F N5 O5
SR Chemical Library
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L10 ANSWER 17 OF 23 REGISTRY COPYRIGHT 2003 ACS
RN 318991-28-5 REGISTRY
CN 4H-1-Benzopyran-2-carboxamide,
N-[[3-(2-fluoro-4-hydroxyphenyl)-1,2,4-
oxadiazol-5-yl]methyl]-N-[3-(1H-imidazol-1-yl)propyl]-6-methyl-4-oxo-
(9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C26 H22 F N5 O5
SR Chemical Library
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L10 ANSWER 18 OF 23 REGISTRY COPYRIGHT 2003 ACS
RN 318991-26-3 REGISTRY
CN 2H-1-Benzopyran-3-carboxamide,
6-bromo-N-[[3-(2-fluoro-4-hydroxyphenyl)-
1,2,4-oxadiazol-5-yl]methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2-oxo-
(9CI)
(CA INDEX NAME)
FS 3D CONCORD
MF C25 H19 Br F N5 O5
SR Chemical Library
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L10 ANSWER 19 OF 23 REGISTRY COPYRIGHT 2003 ACS
RN 227466-87-7 REGISTRY
CN 2-Imidazolidinone,
1-[3-[[(2R)-2-[(2S)-3,4-dihydro-2H-1-benzopyran-2-yl]-2-
hydroxyethyl]amino]propyl]-, rel- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C17 H25 N3 O3
CI COM
SR CA

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L10 ANSWER 20 OF 23 REGISTRY COPYRIGHT 2003 ACS
RN 227297-11-2 REGISTRY
CN 2-Imidazolidinone, 1-[3-[[[(2R)-3,4-dihydro-2H-1-benzopyran-2-
yl]methyl]amino]propyl]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C16 H23 N3 O2
CI COM
SR CA

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L10 ANSWER 21 OF 23 REGISTRY COPYRIGHT 2003 ACS
RN 206861-78-1 REGISTRY
CN Phosphonic acid,
[[[[1,6-dihydro-2-[(2-methyl-1-oxopropyl)amino]-6-oxo-9H-

purin-9-yl]acetyl][2-[(9-phenyl-9H-xanthen-9-yl)oxy]ethyl]amino]methyl]-,
monomethyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C34 H35 N6 O8 P
CI COM
SR CA

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L10 ANSWER 22 OF 23 REGISTRY COPYRIGHT 2003 ACS
RN 206861-74-7 REGISTRY
CN Phosphonic acid,
[[[[6-(benzoylamino)-9H-purin-9-yl]acetyl][2-[(9-phenyl-
9H-xanthen-9-yl)oxy]ethyl]amino]methyl]-, monomethyl ester (9CI) (CA
INDEX NAME)
FS 3D CONCORD
MF C37 H33 N6 O7 P
CI COM
SR CA

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L10 ANSWER 23 OF 23 REGISTRY COPYRIGHT 2003 ACS
RN 64060-91-9 REGISTRY
CN Glycinamide, N-[[(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-

[9H]xanthen]-5-yl)amino]thioxomethyl]glycyl-N-[2-(1H-imidazol-1-yl)-2-
oxoethyl]- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Spiro[isobenzofuran-1(3H),9'-[9H]xanthene], glycinamide deriv.
FS 3D CONCORD
MF C30 H24 N6 O8 S

PAGE 1-A



PAGE 1-B

OH

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

```
=> fil caplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                       526.65     526.86

FILE 'CAPLUS' ENTERED AT 12:55:20 ON 02 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 2 Apr 2003  VOL 138 ISS 14
FILE LAST UPDATED: 1 Apr 2003  (20030401/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


=> d his

     (FILE 'HOME' ENTERED AT 12:48:38 ON 02 APR 2003)

     FILE 'REGISTRY' ENTERED AT 12:48:43 ON 02 APR 2003
L1             STRUCTURE UPLOADED
L2            34 S L1 FUL
L3            15 S L2 AND CAPLUS/LC
L4            19 S L2 NOT L3
L5             STRUCTURE UPLOADED
L6          6797 S L5 FUL
L7             STRUCTURE UPLOADED
L8           137 S L7 FUL
L9           114 S L8 AND CAPLUS/LC
L10           23 S L8 NOT L9

     FILE 'CAPLUS' ENTERED AT 12:55:20 ON 02 APR 2003

=> s l8
L11          42 L8

=> d 1-42 ibib abs hitstr
```

L11 ANSWER 1 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:539473 CAPLUS
DOCUMENT NUMBER: 137:109293
TITLE: Preparation of piperazinylchromans as 5-HT1B and 5-HT1D agonists/antagonists useful as antimigraine drugs.
INVENTOR(S): Chapdelaine, Marc; Davenport, Timothy; Haeberlein, Markus; Horchler, Carey; McCauley, John; Pierson, Edward; Sohn, Daniel
PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.
SOURCE: PCT Int. Appl., 139 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002055014	A2	20020718	WO 2002-SE70	20020115
WO 2002055014	A3	20021114		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-262109P P 20010116
SE 2001-3646 A 20011101
OTHER SOURCE(S): MARPAT 137:109293
GI



I

L11 ANSWER 1 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)
AB Title compds. [I; R1 = H, thiomethoxy, NHA, NA2, NHCOA, halo, OH, OA, cyano, aryl, (substituted) alkyl, cycloalkyl, etc.; A = (substituted) alkyl, cycloalkyl, alkenyl, alkynyl; R2 = (substituted) piperazinyl, homopiperazinyl, aminoalkylamino, aminoheterocyclyl, heterocyclylamino; R6 = H, Me; Y = CONH, CONA, CSNH, CH2CO, CH2NA, piperazinylcarbonyl, 5-membered heterocyclylene, etc.; R7 = (substituted) mono- or bicyclic aryl, heterocyclyl], were prepd. Thus, 8-(4-methyl-1-piperazinyl)chroman-2-carboxylic acid hydrochloride (prepn. given) in DMF was treated sequentially with 1-hydroxybenzotriazole, O-(1H-benzotriazol-1-yl)-N,N,N',N'-pentamethyleneuronium tetrafluoroborate, Et3N, and 4-(4-morpholinyl)aniline (prepn. given) followed by stirring overnight to give 8-(4-methyl-1-piperazinyl)chroman-2-carboxylic acid (4-morpholin-4-ylphenyl)amide. Several I showed 5-HT1B antagonist activity in the range 0.006-5.5 mg/kg in a screen for reversal of hypothermia in guinea pigs.
IT **442548-33-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of piperazinylchromans as 5-HT1B and 5-HT1D agonists/antagonists useful as antimigraine drugs)
RN 442548-33-6 CAPLUS
CN 4H-1-Benzopyran-2-carboxamide, N-[4-(1H-imidazol-1-yl)phenyl]-8-(4-methyl-1-piperazinyl)-4-oxo- (9CI) (CA INDEX NAME)



L11 ANSWER 2 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:539472 CAPLUS
DOCUMENT NUMBER: 137:93772
TITLE: Preparation of piperazinylchromenones as 5-HT1B 5-HT1D agonists/antagonists useful as drugs.
INVENTOR(S): Chapdelaine, Marc; Davenport, Timothy; Haeberlein, Markus; Horchler, Carey; McCauley, John; Pierson, Edward; Sohn, Daniel
PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.
SOURCE: PCT Int. Appl., 150 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002055013	A2	20020718	WO 2002-SE69	20020115
WO 2002055013	A3	20021114		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-262109P P 20010116
SE 2001-3647 A 20011101
OTHER SOURCE(S): MARPAT 137:93772
GI



1

L11 ANSWER 2 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)
AB Title compds. [I; R1 = H, thiomethoxy, NHA, NA2, NHCOA, halo, OH, OA, cyano, aryl, (substituted) alkyl, cycloalkyl, etc.; A = (substituted) alkyl, cycloalkyl, alkenyl, alkynyl; R2 = (substituted) piperazinyl, homopiperazinyl, aminoalkylamino, aminoheterocyclyl, heterocyclylamino; R6 = H, Me; Y = CONH, CONA, CSNH, CH2CO, CH2NA, piperazinylcarbonyl, 5-membered heterocyclylene, etc.; R7 = (substituted) mono- or bicyclic aryl, heterocyclyl], were prepd. Thus, 8-(4-methyl-1-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid hydrochloride (prepn. given) in DMF/Et3N was treated sequentially with 1-hydroxybenzotriazole, O-(1H-benzotriazol-1-yl)-N,N,N',N'-pentamethyleneuronium tetrafluoroborate, 4-dimethylaminopyridine, and 4-(4-morpholinyl)aniline (prepn. given) to give 8-(4-methyl-1-piperazinyl)-N-[4-(4-morpholinyl)phenyl]-4-oxo-4H-chromene-2-carboxamide. Several I showed 5-HT1B antagonist activity in the range 0.006-5.5 mg/kg in a screen for reversal of hypothermia in guinea pigs.
IT **442548-33-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of piperazinylchromenones as 5-HT1B 5-HT1D agonists/antagonists useful as drugs)
RN 442548-33-6 CAPLUS
CN 4H-1-Benzopyran-2-carboxamide, N-[4-(1H-imidazol-1-yl)phenyl]-8-(4-methyl-1-piperazinyl)-4-oxo- (9CI) (CA INDEX NAME)



L11 ANSWER 3 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:539471 CAPLUS
DOCUMENT NUMBER: 137:109205
TITLE: Preparation of 4-oxo-4H-chromene-2-carboxamides and
related compounds as antagonists or agonists of serotonin 5HT1B and 5HT1D receptors
INVENTOR(S): Chapdelaine, Marc; Davenport, Timothy; Haeberlein,
Markus; Horchler, Carey; McCauley, John; Pierson, Edward; Sohn, Daniel
PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.
SOURCE: PCT Int. Appl., 147 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002055012	A2	20020718	WO 2002-SE68	20020115
WO 2002055012	A3	20021114		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003013708	A1	20030116	US 2002-51776	20020116

PRIORITY APPLN. INFO.:

US 2001-262107P	P	20010116
SE 2001-3650	A	20011101
WO 2002-SE68	W	20020115

OTHER SOURCE(S): MARPAT 137:109205
GI

L11 ANSWER 3 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)



I



II

III

AB Title compds. I and their pharmaceutically acceptable salts [R1 = H, alkyl, cycloalkyl, thiomethoxy, etc.; R2 = NR3R3; R3 independently = H, (un)substituted alkylamine e.g., alkyl, alkenyl, alkynyl amino-heterocycle, etc; R3-R3 = (un)substituted cycloalkylamine or amino-heterocycle e.g., alkyl, alkenyl, alkynyl, etc; R5 = H, O, S, etc.; R6 = H, Me; R7 = (un)substituted mono-. or bicylo- arom., (un)substituted heterocycle; X = O, N, NH, S; Y = CONH, NHCO, CSNH, etc.] were prepd with the proviso that multiple bonds are sepd. from each other by at least one single bond. For example, condensation of 4-oxo-4H-chromene-2-carboxylic acid II e.g., prepd. from diethylacetylenedicarboxylate and 2-bromo-4-fluorophenol in 5 steps, and 4-morpholin-4-yl-phenylamine provided preferred 4-oxo-4H-chromene-2-carboxamide III. The utility of the compds. of the present invention were tested using a guinea pig hypothermia test, ED50 values for compds. I range from 0.006-5.5 mg/kg. Compds. I are disclosed to be antagonists or agonists of serotonin 5HT1B and 5HT1D receptors (no data provided). Also I are claimed for use in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, etc..

L11 ANSWER 3 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)
IT **442548-33-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of 4-oxo-4H-chromene-2-carboxamides and related compds. as antagonists or agonists of serotonin 5HT1B and 5HT1D receptors)
RN 442548-33-6 CAPLUS
CN 4H-1-Benzopyran-2-carboxamide, N-[4-(1H-imidazol-1-yl)phenyl]-8-(4-methyl-1-piperazinyl)-4-oxo- (9CI) (CA INDEX NAME)



L11 ANSWER 4 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:314932 CAPLUS
DOCUMENT NUMBER: 136:325418
TITLE: Preparation of condensed flavans as bactericides
INVENTOR(S): Afshar, Mohammad Michel; Morley, Stephen David; Murchie, Alastair Iain Hamilton; Drysdale, Martin James; Potter, Andrew John; Bower, Justin Fairfield
PATENT ASSIGNEE(S): Ribotargets Limited, UK
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002032891	A1	20020425	WO 2001-GB4641	20011018

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002010686	A5	20020429	AU 2002-10686	20011018

PRIORITY APPLN. INFO.:

GB 2000-25581	A	20001018
US 2000-241403P	P	20001018
US 2000-255484P	P	20001214
GB 2001-423	A	20010108
US 2001-260444P	P	20010109
US 2001-267506P	P	20010208
WO 2001-GB4641	W	20011018

OTHER SOURCE(S): MARPAT 136:325418
GI

L11 ANSWER 4 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)



AB Title compds. [e.g., I; R = (un)substituted Ph] were prepd. as bacterial
protein translation inhibitors. Thus, resorcinol was cyclocondensed with
cyclohexanone to give I [R = C6H3(OH)2-2,4]. Data for biol. activity of
title compds. were given.

IT **415709-03-4P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of condensed flavans as bactericides)

RN 415709-03-4 CAPLUS

CN Benzamide,
2,4-dihydroxy-N-[3-(1H-imidazol-1-yl)propyl]-5-(1',3',4',9'a-
tetrahydro-6'-hydroxyspiro[cyclohexane-1,9'-[9H]xanthen]-4'a(2'H)-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 5 OF 42 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:136806 CAPLUS
DOCUMENT NUMBER: 137:93977
TITLE: Liquid-phase combinatorial synthesis of diPNA-arginine
conjugates
AUTHOR(S): Leroux, Mary-Lorene; Di Giorgio, Christophe; Patino,
Nadia; Condom, Roger
CORPORATE SOURCE: Laboratoire de Chimie Bio-Organique, UMR 6001, Universite de Nice Sophia-Antipolis, Nice, F-06108,
Fr.
SOURCE: Tetrahedron Letters (2002), 43(9), 1641-1644
CODEN: TELEAY; ISSN: 0040-4039
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 137:93977

AB Considering the promising anti HIV activity displayed by some diPNA-arginine conjugates, a library has been generated to det. the target(s) and mode(s) of action of these presumed multi targets drugs and
to optimize the antiviral properties of lead compds. This library has been prepd. using a combinatorial liq.-phase strategy, involving easily
available N-protected PNA dimeric backbones as building blocks.

IT **441778-91-2P 441778-92-3P 441778-93-4P**
441778-96-7P 441779-01-7P 441779-06-2P
441779-07-3P 441779-08-4P 441779-09-5P
441779-10-8P 441779-11-9P 441779-12-0P
441779-13-1P 441779-14-2P 441779-15-3P
441779-16-4P 441779-17-5P 441779-18-6P
441779-23-3P 441779-24-4P 441779-29-9P
441779-30-2P 441779-35-7P 441779-36-8P
RL: CPN (Combinatorial preparation); CRT (Combinatorial reactant); RCT (Reactant); CMBI (Combinatorial study); PREP (Preparation); RACT (Reactant
or reagent)
(liq.-phase combinatorial synthesis and anti HIV activity of diPNA-arginine conjugates)

RN 441778-91-2 CAPLUS

CN L-Ornithine,
N-[6-[[2-amino-6-(phenylmethoxy)-9H-purin-9-yl]acetyl]-4,10-dioxo-12-phenyl-11-oxa-3,6,9-triazadodec-1-yl]-N-[(2-
propenyloxy)carbonyl]glycyl-4-aminobutanoyl-N5-[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]amino]iminomethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 5 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A



PAGE 1-B



RN 441778-92-3 CAPLUS

CN L-Ornithine,
N-[6-[[2-amino-6-(phenylmethoxy)-9H-purin-9-yl]acetyl]-4,10-dioxo-12-phenyl-11-oxa-3,6,9-triazadodec-1-yl]glycyl-4-aminobutanoyl-N5-[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]amino]iminomethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 5 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A



PAGE 1-B



RN 441778-93-4 CAPLUS

CN L-Ornithine,
N-[[2-amino-6-(phenylmethoxy)-9H-purin-9-yl]acetyl]-N-[6-[[2-amino-6-(phenylmethoxy)-9H-purin-9-yl]acetyl]-4,10-dioxo-12-phenyl-11-oxa-3,6,9-triazadodec-1-yl]glycyl-4-aminobutanoyl-N5-[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]amino]iminomethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-B

RN 441778-96-7 CAPLUS
CN L-Ornithine,
N-[6-[[6-[bis[(1,1-dimethylethoxy)carbonyl]amino]-9H-purin-9-yl]acetyl]-4,10-dioxo-12-phenyl-11-oxa-3,6,9-triazadodec-1-yl]-N-[(2-propenyloxy)carbonyl]glycyl-4-aminobutanoyl-N5-[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]amino]iminomethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 441779-01-7 CAPLUS
CN L-Ornithine,
N-[6-[[6-[bis[(1,1-dimethylethoxy)carbonyl]amino]-9H-purin-9-yl]acetyl]-4,10-dioxo-12-phenyl-11-oxa-3,6,9-triazadodec-1-yl]glycyl-4-aminobutanoyl-N5-[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]amino]iminomethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 441779-06-2 CAPLUS
CN L-Ornithine,
N-[[2-amino-6-(phenylmethoxy)-9H-purin-9-yl]acetyl]-N-[6-[[6-[bis[(1,1-dimethylethoxy)carbonyl]amino]-9H-purin-9-yl]acetyl]-4,10-dioxo-12-phenyl-11-oxa-3,6,9-triazadodec-1-yl]glycyl-4-aminobutanoyl-N5-[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]amino]iminomethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-B



RN 441779-07-3 CAPLUS
CN L-Ornithine,
N-[[2-amino-6-(phenylmethoxy)-9H-purin-9-yl]acetyl]-N-[6-[[4-

[bis[(1,1-dimethylethoxy)carbonyl]amino]-2-oxo-1(2H)-pyrimidinyl]acetyl]-

4,10-dioxo-12-phenyl-11-oxa-3,6,9-triazadodec-1-yl]glycyl-4-aminobutanoyl-
N5-[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-
yl)sulfonyl]amino]iminomethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 441779-08-4 CAPLUS
CN L-Ornithine, N-[[2-amino-6-(phenylmethoxy)-9H-purin-9-yl]acetyl]-N-[6-

[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-4,10-dioxo-12-

phenyl-11-oxa-3,6,9-triazadodec-1-yl]glycyl-4-aminobutanoyl-N5-[[[(3,4-
dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-
yl)sulfonyl]amino]iminomethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 441779-09-5 CAPLUS
CN L-Ornithine,
N-[[2-amino-6-(phenylmethoxy)-9H-purin-9-yl]acetyl]-N-[6-

[(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-4,10-dioxo-12-phenyl-11-
oxa-3,6,9-triazadodec-1-yl]glycyl-4-aminobutanoyl-N5-[[[(3,4-dihydro-

2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]amino]iminomethyl]-,
methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 441779-10-8 CAPLUS
CN L-Ornithine,
N-[[2-amino-6-(phenylmethoxy)-9H-purin-9-yl]acetyl]-N-[6-[(5-

nitro-1H-indol-1-yl)acetyl]-4,10-dioxo-12-phenyl-11-oxa-3,6,9-triazadodec-

1-yl]glycyl-4-aminobutanoyl-N5-[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-
benzopyran-6-yl)sulfonyl]amino]iminomethyl]-, methyl ester (9CI) (CA
INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 441779-11-9 CAPLUS
CN L-Ornithine,
N-[6-[[2-amino-6-(phenylmethoxy)-9H-purin-9-yl]acetyl]-4,10-dioxo-12-phenyl-11-oxa-3,6,9-triazadodec-1-yl]-N-[[6-[bis[(1,1-dimethylethoxy)carbonyl]amino]-9H-purin-9-yl]acetyl]glycyl-4-aminobutanoyl-N5-[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]amino]iminomethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-A



PAGE 1-B



PAGE 1-B



PAGE 2-B

RN 441779-12-0 CAPLUS
CN L-Ornithine,
N-[[6-[bis[(1,1-dimethylethoxy)carbonyl]amino]-9H-purin-9-yl]acetyl]-N-[6-[[6-[bis[(1,1-dimethylethoxy)carbonyl]amino]-9H-purin-9-yl]acetyl]-4,10-dioxo-12-phenyl-11-oxa-3,6,9-triazadodec-1-yl]glycyl-4-aminobutanoyl-N5-[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]amino]iminomethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 2-B



RN 441779-13-1 CAPLUS
CN L-Ornithine,
N-[6-[[4-[bis[(1,1-dimethylethoxy)carbonyl]amino]-2-oxo-1(2H)-pyrimidinyl]acetyl]-4,10-dioxo-12-phenyl-11-oxa-3,6,9-triazadodec-1-yl]-N-[[6-[bis[(1,1-dimethylethoxy)carbonyl]amino]-9H-purin-9-yl]acetyl]glycyl-4-aminobutanoyl-N5-[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]amino]iminomethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A

RN 441779-14-2 CAPLUS
CN L-Ornithine,
N-[[6-[bis[(1,1-dimethylethoxy)carbonyl]amino]-9H-purin-9-

yl]acetyl]-N-[6-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]
-

4,10-dioxo-12-phenyl-11-oxa-3,6,9-triazadodec-1-yl]glycyl-4-aminobutanoyl-
N5-[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-
yl)sulfonyl]amino]iminomethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A

RN 441779-15-3 CAPLUS
CN L-Ornithine,
N-[[6-[bis[(1,1-dimethylethoxy)carbonyl]amino]-9H-purin-9-

yl]acetyl]-N-[6-[(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-4,10-

dioxo-12-phenyl-11-oxa-3,6,9-triazadodec-1-yl]glycyl-4-aminobutanoyl-N5-
[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-
yl)sulfonyl]amino]iminomethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A

RN 441779-16-4 CAPLUS
CN L-Ornithine,
N-[[6-[bis[(1,1-dimethylethoxy)carbonyl]amino]-9H-purin-9-

yl]acetyl]-N-[6-[(5-nitro-1H-indol-1-yl)acetyl]-4,10-dioxo-12-phenyl-11-
oxa-3,6,9-triazadodec-1-yl]glycyl-4-aminobutanoyl-N5-[[[(3,4-dihydro-

2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]amino]iminomethyl]-,
methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L11 ANSWER 5 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-B



PAGE 2-B

RN 441779-17-5 CAPLUS
CN L-Ornithine,
N-[6-[[2-amino-6-(phenylmethoxy)-9H-purin-9-yl]acetyl]-4,10-dioxo-12-phenyl-11-oxa-3,6,9-triazadodec-1-yl]-N-[[4-[bis[(1,1-dimethylethoxy)carbonyl]amino]-2-oxo-1(2H)-pyrimidinyl]acetyl]glycyl-4-aminobutanoyl-N5-[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]amino]iminomethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 5 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A



PAGE 1-B



RN 441779-18-6 CAPLUS
CN L-Ornithine,
N-[[4-[bis[(1,1-dimethylethoxy)carbonyl]amino]-2-oxo-1(2H)-pyrimidinyl]acetyl]-N-[6-[[6-[bis[(1,1-dimethylethoxy)carbonyl]amino]-9H-purin-9-yl]acetyl]-4,10-dioxo-12-phenyl-11-oxa-3,6,9-triazadodec-1-yl]glycyl-4-aminobutanoyl-N5-[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]amino]iminomethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 5 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A



PAGE 1-B



PAGE 2-A

RN 441779-23-3 CAPLUS
CN L-Ornithine,
N-[6-[[2-amino-6-(phenylmethoxy)-9H-purin-9-yl]acetyl]-4,10-dioxo-12-phenyl-11-oxa-3,6,9-triazadodec-1-yl]-N-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]glycyl-4-aminobutanoyl-N5-[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]amino]iminomethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 5 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A



PAGE 1-B



RN 441779-24-4 CAPLUS
CN L-Ornithine,
N-[6-[[6-[bis[(1,1-dimethylethoxy)carbonyl]amino]-9H-purin-9-yl]acetyl]-4,10-dioxo-12-phenyl-11-oxa-3,6,9-triazadodec-1-yl]-N-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]glycyl-4-aminobutanoyl-N5-[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]amino]iminomethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 441779-29-9 CAPLUS
CN L-Ornithine,
N-[6-[[2-amino-6-(phenylmethoxy)-9H-purin-9-yl]acetyl]-4,10-

dioxo-12-phenyl-11-oxa-3,6,9-triazadodec-1-yl]-N-[(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]glycyl-4-aminobutanoyl-N5-[[[(3,4-dihydro-

2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]amino]iminomethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 441779-30-2 CAPLUS
CN L-Ornithine,
N-[6-[[6-[bis[(1,1-dimethylethoxy)carbonyl]amino]-9H-purin-9-

yl]acetyl]-4,10-dioxo-12-phenyl-11-oxa-3,6,9-triazadodec-1-yl]-N-[(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]glycyl-4-aminobutanoyl-N5-[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]amino]iminomethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 441779-35-7 CAPLUS
CN L-Ornithine,
N-[6-[[2-amino-6-(phenylmethoxy)-9H-purin-9-yl]acetyl]-4,10-

dioxo-12-phenyl-11-oxa-3,6,9-triazadodec-1-yl]-N-[(5-nitro-1H-indol-1-

yl)acetyl]glycyl-4-aminobutanoyl-N5-[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]amino]iminomethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L11 ANSWER 5 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 2-B

RN 441779-36-8 CAPLUS
CN L-Ornithine,
N-[6-[[6-[bis[(1,1-dimethylethoxy)carbonyl]amino]-9H-purin-9-

yl]acetyl]-4,10-dioxo-12-phenyl-11-oxa-3,6,9-triazadodec-1-yl]-N-[(5-nitro
-

1H-indol-1-yl)acetyl]glycyl-4-aminobutanoyl-N5-[[[(3,4-dihydro-2,2,5,7,8-
pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]amino]iminomethyl]-, methyl
ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L11 ANSWER 5 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-B



PAGE 2-B



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L11 ANSWER 6 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:743877 CAPLUS
DOCUMENT NUMBER: 136:295013
TITLE: Convergent strategies for the attachment of fluorescing reporter groups to peptide nucleic
acids
in solution and on solid phase
AUTHOR(S): Seitz, Oliver; Kohler, Olaf
CORPORATE SOURCE: MPI for Molecular Physiology, Department of
Chemical
Biology and Institut fur Organische Chemie, Universitat Dortmund, Dortmund, 44227, Germany
SOURCE: Chemistry--A European Journal (2001), 7(18),
3911-3925
CODEN: CEUJED; ISSN: 0947-6539
PUBLISHER: Wiley-VCH Verlag GmbH
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The site-selective conjugation of peptide nucleic acids (PNA) with fluorescent reporter groups is essential for the construction of hybridization probes that can report the presence of a particular DNA sequence. This paper describes convergent methods for the soln.- and solid-phase synthesis of multiply labeled PNA oligomers. The solid-phase
synthesis of protected PNA enabled the selective attachment of fluorescent
labels at the C-terminal end (3' in DNA) which demonstrated that further
manipulations on protected PNA fragments are feasible. For the conjugation to internal sites, a method is introduced that allows for the
on-resin assembly of modified monomers thereby omitting the need to synthesize an entire monomer in soln. Furthermore, it is shown that the
application of a highly orthogonal protecting group strategy in combination with chemoselective conjugation reactions provides access to a
rapid and automatable solid-phase synthesis of dual labeled PNA probes.
Real-time measurements of nucleic acid hybridization were possible by taking advantage of the fluorescence resonance energy transfer (FRET) between suitably appended fluorophoric groups. Analogously to DNA-based
mol. beacons, the dual labeled PNA probes were only weakly fluorescing in
the single-stranded state. Hybridization to a complementary oligonucleotide, however, induced a structural reorganization and conferred a vivid fluorescence enhancement.
IT **230618-04-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(convergent strategies for attachment of fluorescing reporter groups to
peptide nucleic acids in soln. and on solid phase)
RN 230618-04-9 CAPLUS
CN 2,5,8,11,14,17,20,23,26-Nonaazaheptacosanoic acid,
8,14-bis[[1,6-dihydro-6-

L11 ANSWER 6 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)

oxo-2-[[(phenylmethoxy)carbonyl]amino]-9H-purin-9-yl]acetyl]-27-[(3',6'-
dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-5-yl)amino]-

4,10,16,22-tetraoxo-20-[[2-oxo-4-[[(phenylmethoxy)carbonyl]amino]-1(2H)-
pyrimidinyl]acetyl]-27-thioxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX
NAME)

PAGE 1-A



PAGE 2-A





REFERENCE COUNT: 73 THERE ARE 73 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 7 OF 42 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:693264 CAPLUS
DOCUMENT NUMBER: 135:257269
TITLE: Preparation of N-heterocyclyl amide compounds as 5-HT antagonists
INVENTOR(S): Yamada, Akira; Tomishima, Masaki; Hayashida, Hisashi; Imanishi, Masashi; Spears, Glen W.; Ito, Kiyotaka; Takahashi, Fumie; Miyake, Hiroshi
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 239 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001068585	A1	20010920	WO 2001-JP1993	20010313
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001041128	A5	20010924	AU 2001-41128	20010313
EP 1264820	A1	20021211	EP 2001-912338	20010313
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: JP 2000-70127 A 20000314
JP 2000-305947 A 20001005
WO 2001-JP1993 W 20010313
OTHER SOURCE(S): CASREACT 135:257269; MARPAT 135:257269

AB Amides compds. represented by the general formula R1-A-X-NHCO-Y-R2 [wherein R1 is an optionally substituted heterocyclic group or optionally substituted phenyl; R2 is optionally substituted fused Ph, optionally substituted Ph, or optionally substituted thienyl; A is a group represented by the formula -(CH2)t-(O)m- or -(CR3R4)pNR5(CO)n- (wherein R3 and R4 each is hydrogen or R3 and R4 in combination form imino; R5 is hydrogen or lower alkyl; t is 0, 1, or 2; and p, m, and n each is 0 or 1); X is optionally substituted phenylene or an optionally substituted, divalent, nitrogenous heterocyclic group; and Y is a bond, lower alkylene,

L11 ANSWER 7 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)

or lower alkenylene] and salts thereof are prepd. Theses amides include phenylacetamide, cinnamides, 1H-indole-7-carboxamides, 3-(2-pyridyl)-2-propenamides, 5-phenyl-2-thiophenecarboxamides, 9H-carbazolecarboxamides, 3-phenyl-2-propenamides, 9H-fluorene-1-carboxamides, 2,3-dihydrobenz[b]oxepine-4-carboxamides, 1H-benzo[b]thiepin-4-carboxamides, and 3-(1H-indol-3-yl)-2-propenamides. They are antagonists of 5-hydroxytryptamine (5-HT), in particular 5-HT2c, and are useful for the treatment of 5-HT-mediated diseases such as (1) central nervous system disorders in including anxiety, depression, obsessive-compulsive neurosis, migraine headache, anorexia, Alzheimer's disease, sleep disorder, over-eating, and panic, (2) withdrawal symptom caused by cocaine, ethanol, nicotine, and benzodiazepine, (3) schizophrenia, (4) spinal cord injury, and /or (5) head injury such as hydrocephalus. Thus, SOCl2 was added to a soln. of (E)-4-phenyl-3-butenoic acid in benzene, heated under reflux for 1 h, and cooled, followed by adding 3-(imidazol-1-yl)aniline and Et3N, and the resulting mixt. was stirred at room temp. for 1 h to give (3E)-N-[3-(imidazol-1-yl)phenyl]-4-phenyl-3-butenamide (I). I in vitro inhibited by 82% the binding of [3H]mesulergine to 5-HT2c receptor which was prepd. from rat frontal lobe cortex.

IT **361552-23-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-heterocyclyl amide compds. as 5-HT antagonists for treatment of 5-HT-mediated diseases such as central nervous system disorders, drug withdrawal symptom, schizophrenia, spinal code injury, and head injury)

RN 361552-23-0 CAPLUS
CN 2H-1-Benzopyran-3-carboxamide, 6-chloro-N-[3-(4,5-dimethyl-1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



L11 ANSWER 7 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 8 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:360094 CAPLUS
DOCUMENT NUMBER: 134:366874
TITLE: Preparation of dye-labeled imidazoquinolines and analogs as immunomodulators
INVENTOR(S): Wei, Ai-Ping; Tomai, Mark A.; Rice, Michael J.
PATENT ASSIGNEE(S): 3M Innovative Properties Company, USA
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001034709	A1	20010517	WO 2000-US30366	20001103
W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6376669	B1	20020423	US 2000-705072	20001102
EP 1228147	A1	20020807	EP 2000-980282	20001103
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2002120141	A1	20020829	US 2002-78645	20020219
NO 2002001974	A	20020628	NO 2002-1974	20020425

PRIORITY APPLN. INFO.: US 1999-163724P P 19991105
US 2000-705072 A 20001102
WO 2000-US30366 W 20001103
OTHER SOURCE(S): MARPAT 134:366874
GI



I

L11 ANSWER 8 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)

AB Title compds. [I; R1 = ZR; R = dye residue; R2 = H, (un)substituted alkyl, (hetero)aryl(alkyl), etc.; R3,R4 = H, halo, alkyl, alkoxy, etc.; R3R4 = atoms to complete a ring; Z = spacer group], useful, inter alia, for detg. the binding and/or receptor sites of the mols., were prepd. Thus, 3-nitro-4-quinolinol was aminated by H2N(CH2)4CHCO2CMe3 and the reduced product cyclocondensed with MeOCH2CH2COCl to give, in 3 addnl. steps, I [R1 = (CH2)4NHR, R2 = CH2CH2OMe, R3R4 = CH:CHCH:CH] (II; R = H) which was amidated by fluorescein 5-isothiocyanate to give II (R = CSNHZ1R5, R5 = 6-hydroxy-3-oxo-3H-xanthen-9-yl, Z1 = 3-carboxy-1,4-phenylene). Data for biol. activity of 1 prepd. I were given.

IT **339545-42-5P 339545-44-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of dye-labeled imidazoquinolines and analogs as immunomodulators)

RN 339545-42-5 CAPLUS
CN Thiourea,
N-[4-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-N'-(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-5-yl)- (9CI) (CA INDEX NAME)



L11 ANSWER 8 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 339545-44-7 CAPLUS
CN Thiourea,
N-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]-N'-(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-5-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 9 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:139775 CAPLUS
DOCUMENT NUMBER: 134:296091
TITLE: Synthesis and Properties of Peptide Nucleic Acids Containing a Psoralen Unit
AUTHOR(S): Okamoto, Akimitsu; Tanabe, Kazuhito; Saito, Isao
CORPORATE SOURCE: Department of Synthetic Chemistry and Biological Chemistry, Faculty of Engineering, Kyoto University, CREST, Japan Science and Technology Corporation (JST), Kyoto, 606-8501, Japan
SOURCE: Organic Letters (2001), 3(6), 925-927
CODEN: ORLEF7; ISSN: 1523-7060
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 134:296091

AB We prepd. the psoralen PNA unit from 8-methoxypsoralen and synthesized various PNAs contg. psoralen by a typical tBoc method. PNAs contg. psoralen (P-PNA) at strand end formed a stable duplex with complementary DNA. The hybridization of P-PNA with complementary DNA resulted in a considerable decrease of the psoralen fluorescence.

IT **333968-94-8P 333968-96-0P 333968-98-2P 333969-00-9P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and DNA-hybridization characteristics of psoralen-contg. peptide nucleic acids)

RN 333968-94-8 CAPLUS
CN Peptide nucleic acid, (H-[1'-de(6-amino-9H-purin-9-yl)-1'-[(7-oxo-7H-furo[3,2-g][1]benzopyran-9-yl)oxy]]A-G-T-T-C-C-G-C)-NH2 (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



PAGE 3-A



PAGE 4-A



PAGE 5-A



RN 333968-96-0 CAPLUS
CN Peptide nucleic acid,
(H-G-T-T-[1'-de(6-amino-9H-purin-9-yl)-1'-[(7-oxo-7H-furo[3,2-g][1]benzopyran-9-yl)oxy]]A-C-G-C)-NH2 (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



PAGE 2-B



PAGE 3-A



H_2N—

PAGE 3-B



RN 333968-98-2 CAPLUS

PAGE 2-A



PAGE 3-A



CN Peptide nucleic acid,
(H-G-T-T-C-C-[1'-de(6-amino-9H-purin-9-yl)-1'-[(7-oxo-7H-furo[3,2-g][1]benzopyran-9-yl)oxy]]A-C)-NH2 (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 4-A



RN 333969-00-9 CAPLUS
CN Peptide nucleic acid,
(H-G-T-T-C-C-G-T-[1'-de(6-amino-9H-purin-9-yl)-1'-[(7-oxo-7H-furo[3,2-g][1]benzopyran-9-yl)oxy]]A)-NH2 (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



PAGE 3-A



PAGE 4-A



PAGE 5-A



PAGE 6-A



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS
FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L11 ANSWER 10 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:78241 CAPLUS
DOCUMENT NUMBER: 134:131434
TITLE: Preparation of substituted piperidines as nociceptin
receptor ORL-1 agonists for use in treating cough
INVENTOR(S): Tulshian, Deen; Ho, Ginny D.; Silverman, Lisa S.; Matasi, Julius J.; Mcleod, Robbie L.; Hey, John A.; Chapman, Richard W.; Bercovici, Ana; Cuss, Francis M.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001007050	A1	20010201	WO 2000-US1853	20000126
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6262066	B1	20010717	US 1999-359771	19990726
EP 1200087	A1	20020502	EP 2000-904560	20000126
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
BR 2000012801	A	20020507	BR 2000-12801	20000126
JP 2003505420	T2	20030212	JP 2001-511934	20000126
US 2001011092	A1	20010802	US 2001-769824	20010125
US 6455527	B2	20020924		
NO 2002000392	A	20020325	NO 2002-392	20020125

PRIORITY APPLN. INFO.: US 1999-359771 A 19990726
US 1998-94240P P 19980727
WO 2000-US1853 W 20000126
OTHER SOURCE(S): MARPAT 134:131434
GI



I



II

AB The title compds. [I; X1 = (un)substituted alkyl, cycloalkyl, aryl, etc.;
X2 = CHO, CN, (un)substituted NH2, etc.; or X1 = (un)substituted
benzofused heterocyclyl and X2 = H; or X1 and X2 together form an
optionally benzofused spiro heterocyclyl group; R1-R4 = H, alkyl; or (R1
and R4) or (R2 and R3) or (R1 and R3) or (R2 and R4) together can form an
alkylene bridge; Z1 = (un)substituted alkyl, aryl, heteroaryl, etc.; Z2 =
H, Z1; Z3 = H, alkyl; or Z1-Z3, together with the carbon to which they are
attached, form bicyclic satd. or unsatd. rings] and their pharmaceutically
acceptable salts, useful as ORL-1 receptor agonists for the treatment of
cough, alone or in combination with one or more agents for the treatment
of cough, allergy or asthma symptoms, were prepd. and formulated. Thus,
reacting 4-hydroxy-4-phenylpiperidine with .alpha.-bromodiphenylmethane in
the presence of K2CO3 in CH3CN afforded 90% II which showed Ki of 13 nM
against ORL-1 receptor binding.

IT **256941-57-8P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of substituted piperidines as nociceptin receptor ORL-1
agonists for use in treating cough)

RN 256941-57-8 CAPLUS

CN 1,3,8-Triazaspiro[4.5]decan-4-one, 3-[2-(butylamino)ethyl]-8-(3,4-dihydro-2H-1-benzopyran-4-yl)-1-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2000:881146 CAPLUS
DOCUMENT NUMBER: 134:42136
TITLE: Preparation of aminoalkyl substituted benzodioxan, benzofuran or benzopyran derivatives for treating conditions which are related to impaired fundic relaxation
INVENTOR(S): Van Emelen, Kristof; De Bruyn, Marcel Frans Leopold
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000075136	A1	20001214	WO 2000-EP4746	20000523
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000011237	A	20020305	BR 2000-11237	20000523
EP 1187829	A1	20020320	EP 2000-940267	20000523
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003501427	T2	20030114	JP 2001-502419	20000523
EE 200100639	A	20030217	EE 2001-639	20000523
NO 2001005903	A	20011203	NO 2001-5903	20011203

PRIORITY APPLN. INFO.: EP 1999-201747 A 19990602
WO 2000-EP4746 W 20000523
OTHER SOURCE(S): MARPAT 134:42136
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; Alk1 = (un)substituted alkanediyl, alkylcarbonyl,

carbonylalkyl, etc.; Alk2 = alkylcarbonylalkyl, (un)substituted alkanediyl, etc.; Z1Z2 = OCHR4CH2, OCHR4CH2O, OCHR4CH2S, etc.; R1-R3 = H, alkyl, OH, etc.; or when R1 and R2 are on adjacent carbon atoms, R1 and R2 taken together may form (CH2)3, (CH2)4, OCH2CH2, etc.; R4 = H, alkyl, phenylmethyl, etc.; R6 = H, phenylmethyl; R5 = II-IV (wherein X = O, S, NR9, CHNO2; Y = O, S; R7 = H, alkyl, cycloalkyl, etc.; R8 = alkyl, cycloalkyl, Ph, phenylmethyl; R9 = CN, alkyl, cycloalkyl, etc.; R10 = H, alkyl; Q = (CH2)2, (CH2)3, CH2CO, etc.), etc.] and their pharmaceutically acceptable acid addn. salts, useful as a medicine, in particular for treating conditions which are related to impaired fundic relaxation, were prepd. E.g., a multi-step synthesis of the pyrimidinone V.HCl which showed the mean max. change of 5 mL in vol. on relaxation of the fundus, during the 1 h observation period after i.d. administration at 0.63 mg/kg, was given.

IT **312933-47-4P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of aminoalkyl substituted benzodioxan, benzofuran or benzopyran derivs. for treating conditions which are related to impaired fundic relaxation)

RN 312933-47-4 CAPLUS

CN 2,4-Imidazolidinedione, 1-[3-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl](phenylmethyl)amino]-2-hydroxypropyl]- (9CI) (CA INDEX NAME)



IT **312933-48-5P 312933-50-9P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of aminoalkyl substituted benzodioxan, benzofuran or benzopyran

L11 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)
derivs. for treating conditions which are related to impaired fundic
relaxation)
RN 312933-48-5 CAPLUS
CN 2,4-Imidazolidinedione, 1-[3-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]-2-hydroxypropyl]-, monohydrochloride (9CI) (CA INDEX
NAME)



● HCl

RN 312933-50-9 CAPLUS
CN 2,4-Imidazolidinedione, 1-[3-[[(3,4-dihydro-2H-1-benzopyran-3-yl)methyl]amino]-2-hydroxypropyl]-, monohydrochloride (9CI) (CA INDEX
NAME)



● HCl

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 12 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:528837 CAPLUS
DOCUMENT NUMBER: 133:282060
TITLE: Strategies for the synthesis of fluorescently labelled
PNA
AUTHOR(S): Liu, Xiaohai; Balasubramanian, Shankar
CORPORATE SOURCE: Department of Chemistry, University of Cambridge, Lensfield, Cambridge, CB2 1EW, UK
SOURCE: Tetrahedron Letters (2000), 41(32), 6153-6156
CODEN: TELEAY; ISSN: 0040-4039
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 133:282060
AB A simple and effective strategy for prepg. fluorophore-labeled PNA is described. A C-terminal S-t-butylmercaptocysteine-derivatized PNA was prepd. on solid-phase using Fmoc chem. Selective deprotection of the S-t-butylmercapto group on-bead, allowed the free thiol to be reacted with
a fluorophore derivatized via an iodoacetamido or maleimido linker. Subsequent cleavage and sidechain deprotection yielded C-terminal labeled
PNA in good yield and purity. Dual labeled PNA was also prepd. by using
both C-terminal (-SH) and N-terminal (-NH2) labeling chemistries.
IT **299428-50-5DP**, resin-bound **299428-51-6DP**, resin-bound
299428-54-9DP, resin-bound **299428-55-0DP**, resin-bound
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(prepn. of N- or C-terminal fluorescently labeled PNA under solid-phase
synthetic conditions)
RN 299428-50-5 CAPLUS
CN Peptide nucleic acid, ([4-[3,6-bis(dimethylamino)xanthylium-9-yl]-3-carboxybenzoyl]-T-A-G-G-G)-3-[(1,1-dimethylethyl)dithio]-Ala-OH (9CI) (CA
INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 12 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A



PAGE 1-B



RN 299428-51-6 CAPLUS
CN Peptide nucleic acid, ([4-[3,6-bis(dimethylamino)xanthylium-9-yl]-3-carboxybenzoyl]-T-A-G-G-G)-Cys-OH (9CI) (CA INDEX NAME)

L11 ANSWER 12 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)
Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



RN 299428-54-9 CAPLUS
CN Peptide nucleic acid, ([3-[3,6-bis(dimethylamino)xanthylium-9-yl]-4-carboxybenzoyl]-T-A-G-G-G)-3-[(1,1-dimethylethyl)dithio]-Ala-OH (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A

PAGE 2-B



PAGE 2-C

RN 299428-55-0 CAPLUS
CN Peptide nucleic acid, ([3-[3,6-bis(dimethylamino)xanthylium-9-yl]-4-carboxybenzoyl]-T-A-G-G-G)-Cys-OH (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A

PAGE 2-B



PAGE 2-C

IT **299428-47-0P 299428-48-1P 299428-52-7P**
299428-53-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of N- or C-terminal fluorescently labeled PNA under solid-phase
synthetic conditions)

RN 299428-47-0 CAPLUS

CN Peptide nucleic acid, (H-T-A-G-G-G)-S-[(3R)-1-[4-[3,6-bis(dimethylamino)xanthylium-9-yl]-3-carboxyphenyl]-2,5-dioxo-3-pyrrolidinyl]-Cys-OH, inner salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A

PAGE 2-B



RN 299428-48-1 CAPLUS

CN Peptide nucleic acid, (H-T-A-G-G-G)-S-[(3S)-1-[4-[3,6-bis(dimethylamino)xanthylium-9-yl]-3-carboxyphenyl]-2,5-dioxo-3-pyrrolidinyl]-Cys-OH (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A

PAGE 2-B



RN 299428-52-7 CAPLUS
CN Peptide nucleic acid, ([4-[3,6-bis(dimethylamino)xanthylium-9-yl]-3-carboxybenzoyl]-T-A-G-G-G)-S-[2-[(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-5-yl)amino]-2-oxoethyl]-Cys-OH (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A



RN 299428-53-8 CAPLUS
CN Peptide nucleic acid, ([3-[3,6-bis(dimethylamino)xanthylium-9-yl]-4-carboxybenzoyl]-T-A-G-G-G)-S-[2-[(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-5-yl)amino]-2-oxoethyl]-Cys-OH (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L11 ANSWER 12 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-C



PAGE 2-A

PAGE 2-B



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:415473 CAPLUS
DOCUMENT NUMBER: 133:36025
TITLE: Silver halide elements containing yellow couplers with
improved dye stability
INVENTOR(S): Lussier, Barbara B.; Proseus, Michael J.
PATENT ASSIGNEE(S): Eastman Kodak Co., USA
SOURCE: U.S., 17 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6077658	A	20000620	US 1998-216777	19981218
EP 1018668	A2	20000712	EP 1999-204158	19991206
EP 1018668	A3	20001025		
EP 1018668	B1	20020327		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

CN 1258020	A	20000628	CN 1999-126420	19991217
JP 2000181034	A2	20000630	JP 1999-360930	19991220

PRIORITY APPLN. INFO.: US 1998-216777 A 19981218
OTHER SOURCE(S): MARPAT 133:36025
AB This invention relates to a photog. element comprising a silver halide emulsion layer having assocd. therewith a yellow dye-forming coupler which is an acylacetanilide compd. comprising an alkoxy or aryloxy substituent ortho to the nitrogen atom on the acetanilide ring said ring further comprising a substituent contg. a chroman ether group.
IT 273937-26-1
RL: DEV (Device component use); USES (Uses)
(photog. Ag halide elements contg. yellow couplers with improved dye stability)
RN 273937-26-1 CAPLUS
CN 1-Imidazolidineacetamide, N-[5-[[2-[[3,4-dihydro-2,2,4-trimethyl-7-(1,1,3,3-tetramethylbutyl)-2H-1-benzopyran-6-yl]oxy]-1-oxooctyl]amino]-2-methoxyphenyl]-.alpha.-(2,2-dimethyl-1-oxopropyl)-2,5-dioxo-3-(phenylmethyl)- (9CI) (CA INDEX NAME)

L11 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 14 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:161121 CAPLUS
DOCUMENT NUMBER: 132:207763
TITLE: Preparation of benzopyran, tetrahydroquinoline, pyrano[2,3-b]pyridine, and indan derivatives as potassium channel inhibitors
INVENTOR(S): Lloyd, John; Finlay, Heather J.; Vaccaro, Wayne; Atwal, Karnail; Gross, Michael F.; Spear, Kerry L.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 210 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000012077	A1	20000309	WO 1999-US18599	19990816

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2341678	AA	20000309	CA 1999-2341678	19990816
AU 9956753	A1	20000321	AU 1999-56753	19990816
AU 754204	B2	20021107		
EP 1109544	A1	20010627	EP 1999-943714	19990816

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

JP 2002523451	T2	20020730	JP 2000-567195	19990816
US 6150356	A	20001121	US 1999-375955	19990817
US 6511977	B1	20030128	US 2000-670285	20000925

PRIORITY APPLN. INFO.: US 1998-98709P P 19980901
WO 1999-US18599 W 19990816
US 1999-375955 A3 19990817
OTHER SOURCE(S): MARPAT 132:207763
GI

L11 ANSWER 14 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)



I



II

AB The title compds. (I) [wherein A, B, and D = independently CH or N; R = H, (aryl)alkyl, alkenyl, aryl, (hetero)cycloalkyl, or cycloalkylalkyl; R1 = (aryl)alkyl, aryl, alkenyl, heterocyclo, NR5-heterocyclo, (hetero)cycloalkyl, cycloalkylalkyl, or (un)substituted amino; or R and R1 taken together with the N-S atoms = a 5- to 8-membered ring; R2 = H, (aryl)alkyl, acyl, carboxymethyl, carbamoylmethyl, etc.; R3 and R4 = independently = H, (aryl)alkyl, cycloalkyl, or R3 and R4 taken together with the C to which they are attached form a 5- to 8-membered ring; R5 = H, (aryl)alkyl, alkenyl, aryl, or cycloalkyl(alkyl); X1 = (CR3R4)n, O, NR5, S, S(O), SO2, -OCR3R4-, -NR5CR3R4-, -SCR3R4-, -S(O)CR3R4-, or -SO2CR3R4-; n = 1-3; X2 = single bond, NR5, or O; Q = substituted NHCH:NCN, acyl, (un)substituted sulfamoyl, or substituted heterocyclo] were prepd by soln. phase or solid phase synthesis as antiarrhythmics. For example, II was formed in a 3-step sequence involving: (1) sulfonylation of (trans)-4-amino-3,4-dihydro-2,2-dimethyl-6-cyano-2H-benzopyran with 4-ethylbenzenesulfonyl chloride (85%), (2) hydrolysis of the nitrile to the carboxylic acid using aq. Na2O2 (33%), and (3) amidation with 1,2,3,4-tetrahydro-1-naphthylamine (51%). I block the delayed rectifier voltage-gated K+ channel (IKur) and are therefore useful in the prevention and treatment of cardiac arrhythmia (no data).

IT **260398-39-8P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (target compd.; prepn. of arylsulfamido benzopyran, tetrahydroquinoline, pyrano[2,3-b]pyridine, and indan derivs. by soln. phase or solid phase synthesis as potassium channel inhibitors for the treatment of arrhythmia)

RN 260398-39-8 CAPLUS

CN 2H-1-Benzopyran-6-carboxamide, 4-[[(4-ethylphenyl)sulfonyl]amino]-3,4-dihydro-3-hydroxy-N-[3-(1H-imidazol-1-yl)propyl]-2,2-dimethyl-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 15 OF 42 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:98525 CAPLUS

DOCUMENT NUMBER: 132:137396

TITLE: Phenylazole compounds, process for producing the same and drugs for hyperlipemia

INVENTOR(S): Umeda, Nobuhiro; Mochizuki, Nobuo; Uchida, Seiichi; Nishibe, Tadayuki; Yamada, Hirokazu; Ito, Kunihito; Horikoshi, Hiromi

PATENT ASSIGNEE(S): Nippon Soda Co., Ltd., Japan

SOURCE: PCT Int. Appl., 92 pp. CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000006550	A1	20000210	WO 1999-JP4070	19990729
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2339123	AA	20000210	CA 1999-2339123	19990729
AU 9949297	A1	20000221	AU 1999-49297	19990729
AU 753360	B2	20021017		
EP 1101759	A1	20010523	EP 1999-933152	19990729
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2000290280	A2	20001017	JP 1999-216581	19990730
JP 2000281656	A2	20001010	JP 1999-221789	19990804
JP 2000281658	A2	20001010	JP 1999-221790	19990804
US 6342516	B1	20020129	US 2001-744786	20010126

PRIORITY APPLN. INFO.: JP 1998-218316 A 19980731
JP 1998-222157 A 19980805
JP 1999-16846 A 19990126
JP 1999-19670 A 19990128
JP 1999-24318 A 19990201
WO 1999-JP4070 W 19990729

OTHER SOURCE(S): MARPAT 132:137396

GI



I



II



III

AB Phenylpyrazole and phenylimidazole compds. represented by general formula (I; wherein A represents (un)substituted imidazolyl or pyrazolyl; B represents (un)substituted (CH2)k or (CH:CH)k; Y = bond, O, S, SO2, CO, OCH2, C1-5 alkyl-(un)substituted NHCO or NH; Z = (un)substituted and satd. or unsatd. heterocycle contg. 1 to 4 N, O or S atoms, (un)substituted benzoquinonyl or naphthoquinonyl) or pharmaceutically acceptable salts thereof are prepd. Claimed are drugs for hyperlipemia which contain these compds. I as the active ingredient. Among all, compds. wherein Z is substituted chroman-2-yl, 2,3-dihydrobenzofuran-2-yl, etc. have an effect of inhibiting the formation of lipid peroxides too. Thus, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid, 1-(4-aminophenyl)imidazole 4.0, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride 2.82, 1-hydroxybenzotriazole 2.72 g, and 2.5 mL Et3N were added to 30 mL DMF and stirred at room temp. for 20 h to give title compd. (II). II and N-[4-(imidazol-1-yl)phenyl]-1-methyl-3-pyrrrolecarboxamide (III) at 25 mg/kg p.o. lowered total serum level of cholesterol 40 and 75%, resp., and serum triglyceride level by 62 and 91%, resp. A tablet formulation contg. I was prepd.

IT **256660-54-5P 256660-58-9P 256660-68-1P**

256660-70-5P 256660-72-7P 256660-74-9P
256660-76-1P 256660-77-2P 256660-85-2P
256660-88-5P 256660-91-0P 256660-92-1P
256660-93-2P 256661-21-9P 256661-52-6P
256661-70-8P 256661-92-4P 256662-02-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of phenylazole compds. as hypolipidemics and inhibitors of lipid peroxide formation)

RN 256660-54-5 CAPLUS
CN 2H-1-Benzopyran-2-carboxamide, 3,4-dihydro-6-hydroxy-N-[4-(1H-imidazol-1-yl)phenyl]-2,5,7,8-tetramethyl- (9CI) (CA INDEX NAME)



RN 256660-58-9 CAPLUS
CN 2H-1-Benzopyran-2-carboxamide, 3,4-dihydro-6-hydroxy-N-[2-[[4-(1H-imidazol-1-yl)phenyl]amino]-2-oxoethyl]-N,2,5,7,8-pentamethyl- (9CI) (CA INDEX NAME)



RN 256660-68-1 CAPLUS
CN 2H-1-Benzopyran-2-carboxamide, 3,4-dihydro-6-hydroxy-N-[4-(1H-imidazol-1-yl)phenyl]-2,5,7,8-tetramethyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 256660-70-5 CAPLUS
CN 2H-1-Benzopyran-2-carboxamide, 3,4-dihydro-6-hydroxy-N-[4-(1H-imidazol-1-yl)phenyl]-2,5,7,8-tetramethyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 256660-72-7 CAPLUS
CN 2H-1-Benzopyran-2-acetamide, 3,4-dihydro-6-hydroxy-N-[4-(1H-imidazol-1-yl)phenyl]-2,5,7,8-tetramethyl- (9CI) (CA INDEX NAME)



RN 256660-74-9 CAPLUS

CN 2H-1-Benzopyran-2-propanamide, 3,4-dihydro-6-hydroxy-N-[4-(1H-imidazol-1-yl)phenyl]-2,5,7,8-tetramethyl- (9CI) (CA INDEX NAME)



RN 256660-76-1 CAPLUS
CN 2H-1-Benzopyran-2-propanamide, 3,4-dihydro-6-hydroxy-N-[4-(1H-imidazol-1-yl)phenyl]-.alpha.,2,5,7,8-pentamethyl- (9CI) (CA INDEX NAME)



RN 256660-77-2 CAPLUS
CN 2H-1-Benzopyran-2-carboxamide, 3,4-dihydro-6-hydroxy-N-[6-[[4-(1H-imidazol-1-yl)phenyl]amino]-6-oxohexyl]-2,5,7,8-tetramethyl- (9CI) (CA INDEX NAME)



RN 256660-85-2 CAPLUS
CN 2H-1-Benzopyran-2-carboxamide, 6-(benzoyloxy)-3,4-dihydro-N-[6-[[4-(1H-imidazol-1-yl)phenyl]amino]-6-oxohexyl]-2,5,7,8-tetramethyl- (9CI) (CA INDEX NAME)



RN 256660-88-5 CAPLUS
CN 2H-1-Benzopyran-2-carboxamide, 3,4-dihydro-6-hydroxy-N-[5-[[4-(1H-imidazol-1-yl)phenyl]amino]-5-oxopentyl]-2,5,7,8-tetramethyl- (9CI) (CA INDEX NAME)



RN 256660-91-0 CAPLUS
CN 2H-1-Benzopyran-2-carboxamide, 6-(acetyloxy)-3,4-dihydro-N-[4-(1H-imidazol-1-yl)phenyl]-2,5,7,8-tetramethyl- (9CI) (CA INDEX NAME)



RN 256660-92-1 CAPLUS
CN 2H-1-Benzopyran-2-carboxamide, 3,4-dihydro-6-hydroxy-N-[3-(1H-imidazol-1-yl)phenyl]-2,5,7,8-tetramethyl- (9CI) (CA INDEX NAME)



RN 256660-93-2 CAPLUS
CN 2H-1-Benzopyran-2-carboxamide, 3,4-dihydro-6-hydroxy-N-[2-(1H-imidazol-1-yl)phenyl]-2,5,7,8-tetramethyl- (9CI) (CA INDEX NAME)



RN 256661-21-9 CAPLUS
CN 2H-1-Benzopyran-2-carboxamide, 3,4-dihydro-N-[4-(1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 256661-52-6 CAPLUS
CN 4H-1-Benzopyran-2-carboxamide, N-[4-(1H-imidazol-1-yl)phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 256661-70-8 CAPLUS
CN 2H-1-Benzopyran-3-carboxamide, N-[4-(1H-imidazol-1-yl)phenyl]-2-oxo- (9CI) (CA INDEX NAME)



RN 256661-92-4 CAPLUS
CN Acetamide, N-[4-(1H-imidazol-1-yl)phenyl]-2-[(4-oxo-4H-1-benzopyran-2-yl)oxy]- (9CI) (CA INDEX NAME)



RN 256662-02-9 CAPLUS
CN Acetamide, N-[4-(1H-imidazol-1-yl)phenyl]-2-[(4-methyl-2-oxo-2H-1-benzopyran-7-yl)oxy]- (9CI) (CA INDEX NAME)



ACCESSION NUMBER: 2000:98519 CAPLUS
DOCUMENT NUMBER: 132:137290
TITLE: Preparation of piperidine derivatives as high affinity ligands for nociceptin receptor ORL-1
INVENTOR(S): Tulshian, Deen; Ho, Ginny D.; Silverman, Lisa S.; Matasi, Julius J.; McLeod, Robbie L.; Hey, John A.; Chapman, Richard W.; Bercovici, Ana; Cuss, Francis M.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000006545	A1	20000210	WO 1999-US14165	19990726
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2338206	AA	20000210	CA 1999-2338206	19990726
AU 9952056	A1	20000221	AU 1999-52056	19990726
BR 9912495	A	20010502	BR 1999-12495	19990726
EP 1100781	A1	20010523	EP 1999-937174	19990726
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO				
JP 2002521472	T2	20020716	JP 2000-562351	19990726
EP 1258244	A1	20021120	EP 2002-18161	19990726
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY				
NO 2001000467	A	20010326	NO 2001-467	20010126

PRIORITY APPLN. INFO.: US 1998-122878 A 19980727
EP 1999-937174 A3 19990726
WO 1999-US14165 W 19990726

OTHER SOURCE(S): MARPAT 132:137290
GI



I



II

AB Compds. of formula I [wherein: the dotted line represents an optional double bond; X1 = (un)substituted alkyl, cycloalkyl, aryl, heteroaryl or heterocycloalkyl; X2 = CHO, CN, optionally substituted amino, alkyl, or aryl; or X1 = (un)substituted benzofused heterocyclyl and X2 = H; or X1 and X2 together form an optionally benzofused spiro heterocyclyl group; R1, R2, R3 and R4 = independently H and alkyl, or (R1 and R4) or (R2 and R3) or (R1 and R3) or (R2 and R4) together can form an alkylene bridge of 1 to 3 carbon atoms; Z1 = (un)substituted alkyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl, or CO2(alkyl or substituted amino) or CN; Z2 = H or Z1; Z3 = H or alkyl; or Z1, Z2 and Z3, together with the carbon to which they are attached, form bicyclic satd. or unsatd. rings] or pharmaceutically acceptable salt or solvate thereof useful as nociceptin receptor inhibitors for the treatment of pain, anxiety, cough, asthma, depression, and alc. abuse are disclosed. Compd. II showed the Ki value of 13 nM in an in vitro test for ORL-1 receptor binding assay. Formulations are given.

IT **256941-57-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

L11 ANSWER 16 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of piperidine derivs. as high affinity ligands for nociceptin
receptor ORL-1)
RN 256941-57-8 CAPLUS
CN 1,3,8-Triazaspiro[4.5]decan-4-one, 3-[2-(butylamino)ethyl]-8-(3,4-dihydro-2H-1-benzopyran-4-yl)-1-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 17 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:388180 CAPLUS
DOCUMENT NUMBER: 131:44735
TITLE: Preparation of aminoalkylbenzopyrans and analogs as
gastric fundus relaxants
INVENTOR(S): Wigerinck, Piet Tom Bert Paul; Verschueren, Wim Gaston; Schroven, Marc Francis Josephine; De Bruyn,
Marc Frans Leopold
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9929687	A1	19990617	WO 1998-EP7771	19981127
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6133277	A	20001017	US 1998-192686	19981116
CA 2311669	AA	19990617	CA 1998-2311669	19981127
AU 9924127	A1	19990628	AU 1999-24127	19981127
AU 748669	B2	20020606		
EP 1036073	A1	20000920	EP 1998-966603	19981127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9814256	A	20001003	BR 1998-14256	19981127
EE 200000328	A	20010815	EE 2000-200000328	19981127
JP 2001525407	T2	20011211	JP 2000-524281	19981127
ZA 9811081	A	20000622	ZA 1998-11081	19981203
NO 2000002074	A	20000602	NO 2000-2074	20000419
US 6495547	B1	20021217	US 2000-641485	20000818

PRIORITY APPLN. INFO.: EP 1997-203808 A 19971205
US 1998-192686 A3 19981116
WO 1998-EP7771 W 19981127

OTHER SOURCE(S): MARPAT 131:44735
GI

L11 ANSWER 17 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)



I

AB Title compds. [I; R = Z1AR5; R1 = H or 1-3 of halo, alkyl, alkoxy, etc.;
R4 = H or alkyl; R5 = N-attached oxodiazacycloalkyl, etc.; R6 = H, alkyl,
CH2Ph, alkoxycarbonyl, etc.; Z = (CH2)1-3, OCH2, CH:CH, CHR3, etc.; R3R4 =
bond; Z1 = CO, alkylene, etc.; Z2 = alkylene; Z3 = piperidine-1,n-diyl]
were prepd. Thus, (R)-3,4-dihydro-2H-1-benzopyran-2-ylmethyl methanesulfonate (prepn. given) was aminated by 1-(3-aminopropyl)tetrahydro-2(1H)-pyrimidinone to give I [R = R1 = H, R4 = CH2NH(CH2)3R5, R5 = 2-oxotetrahydro-1-pyrimidinyl]. Data for biol. activity of I were given.
IT **227297-12-3P 227297-13-4P 227298-09-1P**
227298-10-4P 227466-86-6P 227466-88-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of aminoalkylbenzopyrans and analogs as gastric fundus relaxants)
RN 227297-12-3 CAPLUS
CN 2-Imidazolidinone, 1-[3-[[[(2R)-3,4-dihydro-2H-1-benzopyran-2-yl]methyl]amino]propyl]-, ethanedicate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 227297-11-2
CMF C16 H23 N3 O2

Absolute stereochemistry.



CM 2

CRN 144-62-7
CMF C2 H2 O4

L11 ANSWER 17 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 227297-13-4 CAPLUS
CN 2-Imidazolidinone, 1-[3-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]propyl]-3-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 227298-09-1 CAPLUS
CN Cyanamide, [1-[3-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl](phenylmethyl)amino]propyl]-4,5-dihydro-5-oxo-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 227298-10-4 CAPLUS
CN 2,4-Imidazolidinedione, 3-[3-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 227466-86-6 CAPLUS
CN 2-Imidazolidinone,
1-[3-[[(2R)-2-[(2R)-3,4-dihydro-2H-1-benzopyran-2-yl]-2-hydroxyethyl]amino]propyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 227466-88-8 CAPLUS
CN 2-Imidazolidinone,
1-[3-[[(2R)-2-[(2S)-3,4-dihydro-2H-1-benzopyran-2-yl]-2-hydroxyethyl]amino]propyl]-, rel-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 227466-87-7
CMF C17 H25 N3 O3

Relative stereochemistry.



CM 2

CRN 144-62-7
CMF C2 H2 O4

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 1999:352219 CAPLUS
DOCUMENT NUMBER: 131:102535
TITLE: Solid phase synthesis of protected peptide nucleic acids
AUTHOR(S): Seitz, Oliver
CORPORATE SOURCE: Institut fur Organische Chemie, Universitat Karlsruhe, Karlsruhe, D-76128, Germany
SOURCE: Tetrahedron Letters (1999), 40(22), 4161-4164
CODEN: TELEAY; ISSN: 0040-4039
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Boc/Z-protected PNA oligomers were synthesized on the solid phase. The use of the allylic HYCRON resin allowed for the application of both Boc- and Fmoc-protecting groups. Highest yields were obtained when the monomeric building block was synthesized on the solid phase rather than loaded as preformed unit. The selective attachment of fluorescent labels at the C-terminal (3') end demonstrated for the first time that further manipulations on protected PNA fragments are feasible.

IT **230618-04-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(solid phase synthesis of protected peptide nucleic acids)

RN 230618-04-9 CAPLUS
CN 2,5,8,11,14,17,20,23,26-Nonaazaheptacosanoic acid, 8,14-bis[[1,6-dihydro-6-oxo-2-[[(phenylmethoxy)carbonyl]amino]-9H-purin-9-yl]acetyl]-27-[(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-5-yl)amino]-4,10,16,22-tetraoxo-20-[[2-oxo-4-[[(phenylmethoxy)carbonyl]amino]-1(2H)-pyrimidinyl]acetyl]-27-thioxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



PAGE 2-B



L11 ANSWER 18 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)
REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 19 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:219800 CAPLUS
DOCUMENT NUMBER: 130:252243
TITLE: Sulfonamide-substituted chromans as potassium channel blockers
INVENTOR(S): Brendel, Joachim; Gerlach, Uwe; Lang, Hans Jochen; Weidmann, Klaus
PATENT ASSIGNEE(S): Hoechst Marion Roussel Deutschland Gmbh, Germany
SOURCE: Eur. Pat. Appl., 67 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 905131	A1	19990331	EP 1998-117809	19980919
EP 905131	B1	20020410		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
DE 19742509	A1	19990401	DE 1997-19742509	19970926
AT 215942	E	20020415	AT 1998-117809	19980919
ES 2175582	T3	20021116	ES 1998-117809	19980919
CN 1212964	A	19990407	CN 1998-119538	19980922
NZ 332029	A	20000428	NZ 1998-332029	19980924
BR 9803974	A	20000509	BR 1998-3974	19980924
CA 2249074	AA	19990326	CA 1998-2249074	19980925
ZA 9808790	A	19990326	ZA 1998-8790	19980925
NO 9804475	A	19990329	NO 1998-4475	19980925
AU 9887083	A1	19990415	AU 1998-87083	19980925
AU 741810	B2	20011213		
JP 11158170	A2	19990615	JP 1998-272167	19980925
US 5955607	A	19990921	US 1998-160304	19980925

PRIORITY APPLN. INFO.: DE 1997-19742509 A 19970926
OTHER SOURCE(S): MARPAT 130:252243
GI



I



II

AB Sulfonylaminochromans I [R1, R2 = H, (un)substituted alkyl, fluoroalkyl, Ph; R1R2 = alkylene; R3 = (un)substituted alkyl, amino; R4 = (un)substituted alkyl, acyl, carbamoyl, carboxyl; R5-R8 = H, halo, (un)substituted alkyl, Ph, OH, SH, acyl, aminosulfonyl, carbamoyl; R9 = H, (un)substituted OH; B = H; R9B = bond] were prepd. for use as antiulcer and antidiarrheal agents and antiarrhythmics. Thus, 5,2-Me(HO)C6H3Ac was cyclized with Et2CO to give 2,2-diethyl-6-methyl-4-chromanone which was reductively aminated with NH4OAc, ethylsulfonylated, and treated with BrCH2CO2Me, followed by ester hydrolysis and amidation to give the chroman II. II had an IC50 for human Isk protein binding of 1 .mu.M.

IT **221619-74-5P 221619-79-0P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of sulfonamide-substituted chromans as potassium channel blockers)

RN 221619-74-5 CAPLUS
CN Pentanamide, 5-[(3,4-dihydro-2,2,6-trimethyl-2H-1-benzopyran-4-yl)(ethylsulfonyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]- (9CI) (CA INDEX NAME)



RN 221619-79-0 CAPLUS
CN Acetamide, 2-[(ethylsulfonyl)(6-fluoro-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)amino]-N-[3-(1H-imidazol-1-yl)propyl]- (9CI) (CA INDEX NAME)

L11 ANSWER 19 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)



L11 ANSWER 19 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 20 OF 42 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:140502 CAPLUS
DOCUMENT NUMBER: 130:252655
TITLE: Synthesis of a new class of HIV-1 inhibitors
AUTHOR(S): Di Giorgio, Audrey Farese; Pairot, Sandrine; Patino, Nadia; Condom, Roger; Di Giorgio, Christophe; Aumelas, Andrd; Aubertin, Anne-Marie; Guedj, Roger
CORPORATE SOURCE: Laboratoire de Chimie Bio-Organique, CNRS ESA 6001, Universite de Nice Sophia-Antipolis, Nice, F-06108, Fr.
SOURCE: Nucleosides & Nucleotides (1999), 18(2), 263-275
CODEN: NUNUD5; ISSN: 0732-8311
PUBLISHER: Marcel Dekker, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A new family of mols. was prepd. as potential inhibitors of the HIV-1 Tat-TAR complex. These compds. are constituted by dinucleotide analogs (PNA dimers) bound, through a linker, to an arginine residue. In this series, several mols. inhibit viral development in cell culture with a micromolar IC50 values and without cellular toxicity until 200.mu.M concn.

IT **221665-17-4P 221665-18-5P 221665-19-6P**
221665-20-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of arginine-linked peptide nucleic acid derivs. as new HIV-1 inhibitors)

RN 221665-17-4 CAPLUS
CN L-Ornithine, N-[6-[[6-[bis[(1,1-dimethylethoxy)carbonyl]amino]-9H-purin-9-yl]acetyl]-4,10-dioxo-12-phenyl-11-oxa-3,6,9-triazadodec-1-yl]-N-[[1,6-dihydro-6-oxo-2-[(phenylmethyl)amino]-9H-purin-9-yl]acetyl]glycyl-.beta.-alanyl-N5-[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]amino]iminomethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 20 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A



PAGE 1-B



L11 ANSWER 20 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 2-A

PAGE 2-B



RN 221665-18-5 CAPLUS
CN L-Ornithine, N-[6-[[6-[bis[(1,1-dimethylethoxy)carbonyl]amino]-9H-purin-9-yl]acetyl]-4,10-dioxo-12-phenyl-11-oxa-3,6,9-triazadodec-1-yl]-N-[[1,6-dihydro-6-oxo-2-[(phenylmethyl)amino]-9H-purin-9-yl]acetyl]glycyl-6-aminohexanoyl-N5-[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]amino]iminomethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 20 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A



PAGE 1-B



PAGE 2-B



RN 221665-19-6 CAPLUS
CN L-Ornithine,
N-[[6-[bis[(1,1-dimethylethoxy)carbonyl]amino]-9H-purin-9-

yl]acetyl]-N-[6-[[1,6-dihydro-6-oxo-2-[(phenylmethyl)amino]-9H-purin-9-
yl]acetyl]-4,10-dioxo-12-phenyl-11-oxa-3,6,9-triazadodec-1-yl]glycyl-

.beta.-alanyl-N5-[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-
yl)sulfonyl]amino]iminomethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-A



PAGE 1-B



PAGE 2-B

PAGE 1-B



PAGE 2-B

RN 221665-20-9 CAPLUS
CN L-Ornithine,
N-[[6-[bis[(1,1-dimethylethoxy)carbonyl]amino]-9H-purin-9-

yl]acetyl]-N-[6-[[1,6-dihydro-6-oxo-2-[(phenylmethyl)amino]-9H-purin-9-

yl]acetyl]-4,10-dioxo-12-phenyl-11-oxa-3,6,9-triazadodec-1-yl]glycyl-6-

aminohexanoyl-N5-[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-
yl)sulfonyl]amino]iminomethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 21 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1998:223897 CAPLUS
DOCUMENT NUMBER: 128:321856
TITLE: Synthesis and hybridization properties of an acyclic
achiral phosphonate DNA analog
AUTHOR(S): Kehler, Jan; Henriksen, Ulla; Vejbjerg, Helene; Dahl,
Otto
CORPORATE SOURCE: Department of Chemistry, The H. C. Orsted Institute,
University of Copenhagen, Copenhagen, DK-2100, Den.
SOURCE: Bioorganic & Medicinal Chemistry (1998), 6(3), 315-322
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Protected N-(2-hydroxyethyl)-N-(nucleobase-acetyl)aminomethanephosphonic acids of all four DNA nucleobases have been prepd. and oligomerized by solid-phase synthesis. Four DNA decamers contg. 1-10 of these "PPNA" monomers were prepd. and evaluated by Tm measurements (medium salt) for binding to their DNA and RNA complements. One central modification reduced the binding strongly (.DELTA.Tm = -10.degree.C), but contiguous PPNA monomers gave smaller effects, and the all-PPNA decamer bound to RNA with a .DELTA.Tm of -1.2.degree.C per modification. Thus PPNA oligomers are inferior DNA and RNA binders compared to the closely related and strongly binding PNA oligomers.
IT **206861-70-3P 206861-72-5P 206861-75-8P**
206861-79-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and hybridization properties of an acyclic achiral phosphonate DNA analog)
RN 206861-70-3 CAPLUS
CN Phosphonic acid, [[[[6-(benzoylamino)-9H-purin-9-yl]acetyl][2-[(9-phenyl-9H-xanthen-9-yl)oxy]ethyl]amino]methyl]-, dimethyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 21 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A



PAGE 2-A



RN 206861-75-8 CAPLUS
CN Phosphonic acid, [[[[6-(benzoylamino)-9H-purin-9-yl]acetyl][2-[(9-phenyl-9H-xanthen-9-yl)oxy]ethyl]amino]methyl]-, monomethyl ester, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 206861-74-7
CMF C37 H33 N6 O7 P

L11 ANSWER 21 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A



PAGE 2-A



RN 206861-72-5 CAPLUS
CN Phosphonic acid, [[[[1,6-dihydro-2-[(2-methyl-1-oxopropyl)amino]-6-oxo-9H-purin-9-yl]acetyl][2-[(9-phenyl-9H-xanthen-9-yl)oxy]ethyl]amino]methyl]-, dimethyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 21 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A



PAGE 2-A



CM 2

CRN 121-44-8
CMF C6 H15 N

RN 206861-79-2 CAPLUS
CN Phosphonic acid, [[[[1,6-dihydro-2-[(2-methyl-1-oxopropyl)amino]-6-oxo-9H-purin-9-yl]acetyl][2-[(9-phenyl-9H-xanthen-9-yl)oxy]ethyl]amino]methyl]-, monomethyl ester, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX

L11 ANSWER 21 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)
NAME)

CM 1

CRN 206861-78-1
CMF C34 H35 N6 O8 P

PAGE 1-A



PAGE 2-A



CM 2

CRN 121-44-8
CMF C6 H15 N

L11 ANSWER 21 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 22 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1997:499168 CAPLUS
DOCUMENT NUMBER: 127:190649
TITLE: Preparation of 9-aralkyl-9-fluorenecarboxamides and analogs as microsomal triglyceride transfer protein inhibitors
INVENTOR(S): Biller, Scott A.; Dickson, John K.; Lawrence, R. Michael; Magnin, David R.; Poss, Michael A.; Robl, Jeffrey A.; Slusarchyk, William A.; Sulsky, Richard B.; Tino, Joseph A.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA
SOURCE: PCT Int. Appl., 615 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9726240	A1	19970724	WO 1997-US587	19970113
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2236684	AA	19970724	CA 1997-2236684	19970113
AU 9718285	A1	19970811	AU 1997-18285	19970113
AU 716729	B2	20000302		
CN 1209803	A	19990303	CN 1997-191713	19970113
EP 904262	A1	19990331	EP 1997-903805	19970113
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
BR 9707607	A	19990727	BR 1997-7607	19970113
JP 2000502355	T2	20000229	JP 1997-526127	19970113
ZA 9700328	A	19970715	ZA 1997-328	19970115
NO 9803268	A	19980715	NO 1998-3268	19980715

PRIORITY APPLN. INFO.: US 1996-10346P P 19960116
US 1996-17224P P 19960509
US 1996-30370P P 19961105
WO 1997-US587 W 19970113

OTHER SOURCE(S): MARPAT 127:190649
GI

L11 ANSWER 22 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)



I

AB R2Z4Z3ZZ2Z1R1 [R1 = H, (cyclo)alk(en)yl, alkoxy, (hetero)aryl(oxy), etc.; R2 = groups cited for R1, haloalkyl, etc.; Z = CO, SO0-2, CR(OH); R = H, alkyl, aryl; Z1 = (O- or NH-interrupted)(oxo)alk(en)ylene, etc.; Z2 = (un)substituted 9H-fluoren-9-ylidene, 9H-xanthen-9-ylidene, etc.; Z3 = bon, O, NR5; R5 = H or alkyl; R2R5 = atoms to form a ring; Z4 = bond, groups cited for Z1] were prepd as microsomal triglyceride transfer protein inhibitors (no data). Thus, 9H-fluorene-9-carboxylic acid was alkylated by TsOCH2CH2C.tplbond.CH and the product amidated by H2NCH2CF3 9-(3-butynyl)-N-(2,2,2-trifluoroethyl)fluorene-9-carboxamide which was arylated by 2-bromo-5-nitropyridine to give, after redn. and BzCl amidation, title compd. I.

IT **194210-71-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 9-aralkyl-9-fluorenecarboxamides and analogs as microsomal triglyceride transfer protein inhibitors)

RN 194210-71-4 CAPLUS
CN 9H-Xanthene-9-carboxamide, N-[2-(2-oxo-1-imidazolidinyl)ethyl]-9-(3-phenylpropyl)- (9CI) (CA INDEX NAME)

L11 ANSWER 22 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)



L11 ANSWER 23 OF 42 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1997:433584 CAPLUS
DOCUMENT NUMBER: 127:81770
TITLE: Fluorescein-Conjugated Lysine Monomers for Solid Phase
Synthesis of Fluorescent Peptides
AUTHOR(S): Lohse, Jesper; Nielsen, Peter E.; Harrit, Niels; Dahl,
Otto
CORPORATE SOURCE: Department of Chemistry H. C. Orsted Institute, University of Copenhagen, Copenhagen, DK-2100, Den.
SOURCE: Bioconjugate Chemistry (1997), 8(4), 503-509
CODEN: BCCHES; ISSN: 1043-1802
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Fluorescein Et ester was used to prep. the fluorescent mixed ester/ether
6-O-(carboxymethyl)fluorescein Et ester. Conjugation of the latter fluorescein deriv. to the .epsilon.-amino group of .alpha.-N-Boc-L-lysine,
via the N-hydroxysuccinimde ester, gave the Boc-protected fluorescein-conjugated lysine monomer. Removal of the Boc group, followed
by reaction with Fmoc chloride, gave the Fmoc-protected monomer. These
Boc- and Fmoc-protected fluorescein-conjugated lysines were readily incorporated into peptides and PNA oligomers during solid phase synthesis
to give fluorescent products. Mass spectroscopy and UV studies showed that the fluorophore remains unchanged during solid phase synthesis. In
contrast to fluorescein, the photophys. properties of these derivs. are pH
independent from pH 3 to 8, with a molar absorption coeff., .epsilon.max
456, of 2.9 .times. 104 M-1 cm-1 and fluorescence quantum yield, .phi.f,
of 0.18.

IT **191791-31-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(fluorescein-conjugated lysine monomers for solid phase synthesis of
fluorescent peptides)

RN 191791-31-8 CAPLUS
CN Peptide nucleic acid, (acetyl-T-N6-[[[9-[2-(ethoxycarbonyl)phenyl]-3-oxo-3H-xanthen-6-yl]oxy]acetyl]-Lys-C-G-T-A)-Lys-NH2 (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 23 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A



PAGE 1-B



L11 ANSWER 23 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-C





PAGE 2-A





PAGE 2-C



L11 ANSWER 24 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1997:113481 CAPLUS
DOCUMENT NUMBER: 126:115395
TITLE: Fluorescent labeling reagents
INVENTOR(S): Ahlem, Clarence N.; Torkelson, Steven M.
PATENT ASSIGNEE(S): Systemix, USA
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9641174	A1	19961219	WO 1996-US10178	19960603
W: AL, AM, AT, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, CZ, DE,				
DE, DK, DK, EE, EE, ES, FI, FI, GB, GE, HU, IL, IS, JP, KE, KG,				
KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO,				
NZ, PL				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,				
IE, IT, LU, MC, NL, PT, SE, BF				
US 5650512	A	19970722	US 1995-484961	19950607
AU 9663847	A1	19961230	AU 1996-63847	19960603
US 5955612	A	19990921	US 1997-862746	19970523

PRIORITY APPLN. INFO.: US 1995-484961 19950607
WO 1996-US10178 19960603
OTHER SOURCE(S): CASREACT 126:115395; MARPAT 126:115395
GI



I

AB A class of sulforhodamine labeling reagents capable of binding with a biomol. species to produce a conjugate with fluorescent properties is disclosed. The sulforhodamine labeling reagents have structure I. The group X is selected from an alkyl, an olefin, a monocyclic aliph. satd.

L11 ANSWER 24 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 2-A



L11 ANSWER 24 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)
hydrocarbon, an aryl, or nothing at all. Alkyl denotes an acyclic satd. aliph. straight or branched chain hydrocarbon. An olefin denotes an unsatd. aliph. hydrocarbon. An aryl is used to denote an arom. ring, a substituted arom. ring, and fused arom. rings. The group Y is selected from an amide, a substituted amide, or nothing at all. The group Z is selected from a monocyclic aliph. hydrocarbon, an aryl, or an alkyl, as defined with respect to group X, a polyethylene glycol chain of the general from (CH2CH2O)n, or nothing at all. The alkyl or polyethylene glycol chain may further have inert intermediate amide, ether, or disulfide functionalities. The group X, group Y, and group Z cannot all be nothing at all or non-existent. The group R is an electrophilic moiety suitable for conjugation of the fluorescent labeling reagent with a biomol. species. Also disclosed in a method of making the reagents.
IT **186188-44-3P**
RL: ARG (Analytical reagent use); SPN (Synthetic preparation); ANST (Analytical study); PREP (Preparation); USES (Uses)
(sulforhodamine-based fluorescent labeling reagents for biomols.)
RN 186188-44-3 CAPLUS
CN 1H,5H,11H,15H-Xantheno[2,3,4-ij:5,6,7-i'j']diquinolizin-18-ium, 2,3,6,7,12,13,16,17-octahydro-9-[4-[[[2-[[5-(1H-imidazol-1-yl)-1,5-dioxopentyl]amino]ethyl]amino]sulfonyl]-2-sulfophenyl]-, inner salt (9CI)
(CA INDEX NAME)

PAGE 1-A



L11 ANSWER 25 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1996:494615 CAPLUS
DOCUMENT NUMBER: 125:167686
TITLE: 5-Aminoflavone derivatives with antiestrogenic, antibacterial and antitumor activity
INVENTOR(S): Akama, Tsutomu; Ikeda, Shun-ichi; Shida, Yasushi; Kasai, Masaji; Ishida, Hiroyuki; Kimura, Uichiro; Gomi, Katsushige; Saito, Hiromitsu; Ueno, Kimihisa
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
SOURCE: U.S., 81 pp., Cont.-in-part of U.S. Ser. No. 288,301, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5539112	A	19960723	US 1995-464093	19950605
CA 2187197	AA	19960815	CA 1996-2187197	19960131
WO 9624592	A1	19960815	WO 1996-JP181	19960131
W: AU, CA, JP, KR				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9645474	A1	19960827	AU 1996-45474	19960131
EP 755928	A1	19970129	EP 1996-901492	19960131
EP 755928	B1	20020410		
R: DE, FR, GB, IT				

PRIORITY APPLN. INFO.:
JP 1992-28113 A 19920214
US 1993-14696 B1 19930208
JP 1993-199310 A 19930811
JP 1993-204356 A 19930818
US 1994-206264 B2 19940307
US 1994-288301 B2 19940810
JP 1995-17741 A 19950206
WO 1996-JP181 W 19960131
OTHER SOURCE(S): MARPAT 125:167686
GI



I

AB 5-Aminoflavone derivs. represented by the formula I, wherein R1, R2, R3

L11 ANSWER 25 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)
and R4 are the same or different and represent hydrogen, substituted or
unsubstituted lower alkyl, lower alkenyl, halogen-substituted or
unsubstituted lower alkanoyl or lower alkoxycarbonyl, X1, X2, Y1 and Y2
are the same or different and represent hydrogen, halogen or lower alkyl,
at least one of X1 and X2 represents halogen or lower alkyl, X3 represents
hydrogen, substituted or unsubstituted lower alkyl, lower alkenyl, lower
alkynyl, halogen, hydroxy, substituted or unsubstituted lower alkoxy,
NR5R6 (wherein R5 and R6 are the same or different and represent hydrogen,
or substituted or unsubstituted lower alkyl, or R5 and R6 are taken
together to form a heterocyclic group contg. the nitrogen atom in the
ring), lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, carboxy,
lower alkoxycarbonyl, lower alkanoyl, azido, cyano, substituted or
unsubstituted carbamoyl or lower alkylthiothiocarbonyl: or
pharmaceutically acceptable salts thereof. I were tested for
antiestrogenic, antibacterial and antitumor activity.
IT **152169-54-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); IMF (Industrial manufacture); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); USES (Uses)
(prepn. of 5-aminoflavone derivs. with antiestrogenic, antibacterial
and antitumor activity)
RN 152169-54-5 CAPLUS
CN 4H-1-Benzopyran-4-one,
5-amino-6,8-difluoro-2-[3-fluoro-4-[[6-(1H-imidazol-1-yl)hexyl]amino]phenyl]- (9CI) (CA INDEX NAME)



IT **152169-53-4P 180595-95-3P**
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 5-aminoflavone derivs. with antiestrogenic, antibacterial
and antitumor activity)
RN 152169-53-4 CAPLUS
CN 4H-1-Benzopyran-4-one,
5-amino-6,8-difluoro-2-[3-fluoro-4-[[3-(1H-imidazol-1-yl)propyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 180595-95-3 CAPLUS
CN 4H-1-Benzopyran-4-one,
5-amino-6,8-difluoro-2-[3-fluoro-4-[[6-(1H-imidazol-1-yl)hexyl]amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L11 ANSWER 26 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1994:631379 CAPLUS
DOCUMENT NUMBER: 121:231379
TITLE: Preparation of salmon calcitonin and its pharmaceutical use
INVENTOR(S): Yotsuto, Haa Kooto
PATENT ASSIGNEE(S): Sato Pharma, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06016694	A2	19940125	JP 1992-174236	19920701
PRIORITY APPLN. INFO.:			JP 1992-174236	19920701

GI



II

AB Salmon calcitonin (I), useful for treatment of osteoporosis, Paget's disease, Ca disorder, and osteoclastic carcinoma (no data), is prepd. in a high yield by condensation of protected cyclic peptide II, Fmoc-Lys(Boc)-Leu-Ser(tBu)-Gln-Glu(OtBu)-Leu-OH, His-Lys-Leu-Gln-Thr-Tyr-Pro-OH, and Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro-NH2. Coupling of II with H-Lys(Boc)-Leu-Ser(tBu)-Gln-Glu(OtBu)-Leu-His(Bum)-Lys(Boc)-Leu-Gln-Thr(tBu)-Tyr(tBu)-Pro-Arg(Pmc)-Thr(tBu)-Asn-Thr(tBu)-Gly-Ser(tBu)-Gly-Thr(tBu)-Pro-NH2 in DMF at 0.degree. in the presence of EDPA, HOBT, and TBTU gave 100% protected I, which was treated with 95% TFA to afford I acetate.
IT **158000-59-0P 158000-60-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(prepn. and reaction of)
RN 158000-59-0 CAPLUS
CN L-Prolinamide,
1-[[(2-methyl-1-oxopropyl)amino]methyl]-L-histidyl-N6-[(1,1-dimethylethoxy)carbonyl]-L-lysyl-L-leucyl-L-glutaminyl-O-(1,1-dimethylethyl)-L-threonyl-O-(1,1-dimethylethyl)-L-tyrosyl-L-prolyl-N5-[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]amino]iminomethyl]-L-ornithyl-O-(1,1-dimethylethyl)-L-threonyl-L-asparaginyl-O-(1,1-dimethylethyl)-L-threonylglycyl-O-(1,1-dimethylethyl)-L-serylglycyl-O-(1,1-dimethylethyl)-L-threonyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



●2 HCl

RN 158000-60-3 CAPLUS
CN L-Prolinamide,
N6-[(1,1-dimethylethoxy)carbonyl]-L-lysyl-L-leucyl-O-(1,1-

dimethylethyl)-L-seryl-L-glutaminyl-L-.alpha.-glutamyl-L-leucyl-1-[[(2-methyl-1-oxopropyl)amino]methyl]-L-histidyl-N6-[(1,1-dimethylethoxy)carbonyl]-L-lysyl-L-leucyl-L-glutaminyl-O-(1,1-

dimethylethyl)-L-threonyl-O-(1,1-dimethylethyl)-L-tyrosyl-L-prolyl-N5-[[[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-

yl)sulfonyl]amino]iminomethyl]-L-ornithyl-O-(1,1-dimethylethyl)-L-threonyl-

L-asparaginyl-O-(1,1-dimethylethyl)-L-threonylglycyl-O-(1,1-dimethylethyl)-

L-serylglycyl-O-(1,1-dimethylethyl)-L-threonyl-, 1,1-dimethylethyl ester
(9Cl) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D

L11 ANSWER 27 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1994:106766 CAPLUS
DOCUMENT NUMBER: 120:106766
TITLE: 5-aminoflavone derivative antibiotics and antitumor agents
INVENTOR(S): Akama, Tsutomu; Shida, Yasushi; Ikeda, Shunichi; Kasai, Masaji; Ishida, Hiroyuki; Kimura, Uichiroi; Gomi, Katsushige; Saito, Hiromitsu; Ueno, Kimihisa
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 52 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 556720	A1	19930825	EP 1993-102139	19930211
EP 556720	B1	19970917		
R: DE, FR, GB, IT				
JP 05286962	A2	19931102	JP 1993-14597	19930201

PRIORITY APPLN. INFO.: JP 1992-28113 A 19920214
OTHER SOURCE(S): MARPAT 120:106766
GI



I

AB The title compds. I [R1-R4 = H, (un)substituted lower alkyl, lower alkenyl, halogen, substituted or unsubstituted lower alkanoyl or lower alkoxycarbonyl; X1, X2, Y1, Y2 = H, halogen; provided that .gtoreq.1 of X1
and X2 = halogen], which have antibacterial and antitumor activity, are
prepd. Thus,
5-amino-6,8-difluoro-2-[4-[(3-phthalimidopropyl)amino]phenyl]-4H-1-benzopyran-4-one was reacted with hydrazine monohydrate, producing

5-amino-2-[4-[(3-aminopropyl)amino]phenyl]-6,8-difluoro-4H-1-benzopyran-4-one, which demonstrated min. inhibitory concn. against Bacillus subtilis
of 2.6.mu. g/mL.
IT **152169-53-4 152169-54-5**

L11 ANSWER 27 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); BIOL (Biological study)
(antibiotic and antitumor activity of)
RN 152169-53-4 CAPLUS
CN 4H-1-Benzopyran-4-one,
5-amino-6,8-difluoro-2-[3-fluoro-4-[[3-(1H-imidazol-
1-yl)propyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 152169-54-5 CAPLUS
CN 4H-1-Benzopyran-4-one,
5-amino-6,8-difluoro-2-[3-fluoro-4-[[6-(1H-imidazol-
1-yl)hexyl]amino]phenyl]- (9CI) (CA INDEX NAME)



IT **152168-85-9P 152169-53-4P 152169-54-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and antibiotic and antitumor activity of, reaction of)
RN 152168-85-9 CAPLUS
CN 4H-1-Benzopyran-4-one,
5-amino-6,8-difluoro-2-[3-fluoro-4-[[6-(1H-imidazol-
1-yl)hexyl]amino]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)

L11 ANSWER 27 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)



●x HCl

RN 152169-53-4 CAPLUS
CN 4H-1-Benzopyran-4-one,
5-amino-6,8-difluoro-2-[3-fluoro-4-[[3-(1H-imidazol-
1-yl)propyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 152169-54-5 CAPLUS
CN 4H-1-Benzopyran-4-one,
5-amino-6,8-difluoro-2-[3-fluoro-4-[[6-(1H-imidazol-
1-yl)hexyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L11 ANSWER 28 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1991:536094 CAPLUS
DOCUMENT NUMBER: 115:136094
TITLE: Preparation of (2S,4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2-carbohydrazides and -carboxamides as aldose reductase inhibitors
INVENTOR(S): Kurono, Masayasu; Unno, Ryoichi; Kimura, Hiromoto; Tomiya, Noboru; Sawai, Kiichi; Miura, Kenji; Usui, Toshinao; Kondo, Yasuaki; Tanaka, Yukiya; et al.
PATENT ASSIGNEE(S): Sanwa Kagaku Kenkyusho Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 31 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 418834	A1	19910327	EP 1990-117960	19900918
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 03106885	A2	19910507	JP 1989-242301	19890920
JP 2922930	B2	19990726		
JP 04009384	A2	19920114	JP 1990-110136	19900427
JP 06099308	B4	19941207		
JP 04009385	A2	19920114	JP 1990-110137	19900427
US 5164391	A	19921117	US 1990-582039	19900913
PRIORITY APPLN. INFO.:			JP 1989-242301	19890920
			JP 1990-110136	19900427
			JP 1990-110137	19900427

OTHER SOURCE(S): MARPAT 115:136094
GI



AB The title compds. [I; R = CONHNHR1, CONHOR2, CONR3R4, CONH(CH2)mNR5R6, CONH(CH2)nR7; R1 = H, alkyl, alkanoyl, furyl, thienyl, (un)substituted Ph or naphthyl; R2 = H, alkyl, (un)substituted Ph; R3, R4 = any of definitions for R2, aralkyl; R3R4N may form (un)substituted C5-6 satd. heterocyclyl optionally contg. N or O; R5R6N = (un)substituted satd.

L11 ANSWER 28 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)
heteroring optionally contg. N, O; Q = H, (CH2)rNR8R9; R7 = nitroxy radical, heteroaryl; R8, R9 = (un)substituted alkyl; R8R9N as defined for R5R6N; R10, R11 = H, halo, alkyl(mercapto), alkoxy; X = O, N; m, n, r = 2-5] and their salts, aldose reductase inhibitors useful for the treatment of circulatory diseases and complications of diabetes, were prepd.

(2S,4S)-6-Fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2-carboxylic acid was converted (quant.) to its chloride by SOCl2 and stirred for 18 h at 25.degree. with PhNHNH2 and Et3N in DMF to give 65.9% (crystd.) title 2-(N'-phenyl)carbohydrazide (II). The latter in vitro inhibited aldose reductase with IC50 = 2.2 .times. 10-8 M vs. 2.0 .times. 10-7 M for sorbinil. II relaxed norepinephrine-induced contraction of guinea pig aorta with IC50 of 8.0 .times. 10-7 M vs. 1.0 .times. 10-4 M for cinnarizine. Tablets contg. II were formulated.

IT **136044-58-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as aldose reductase inhibitor)
RN 136044-58-1 CAPLUS
CN Spiro[4H-1-benzopyran-4,4'-imidazolidine]-2-carboxamide, 6-fluoro-2,3-dihydro-N-[2-(1H-imidazol-1-yl)ethyl]-2',5'-dioxo-, (2S-cis)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L11 ANSWER 29 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1991:449507 CAPLUS
DOCUMENT NUMBER: 115:49507
TITLE: Fluorescent markers for hypoxic cells: a study of nitroaromatic compounds, with fluorescent heterocyclic side chains, that undergo bioreductive binding
AUTHOR(S): Hodgkiss, Richard J.; Jones, Gareth W.; Long, Anthony; Middleton, Richard W.; Parrick, John; Stratford, Michael R. L.; Wardman, Peter; Wilson, George D.
CORPORATE SOURCE: Gray Lab. Cancer Res. Campaign, Northwood/Middlesex, HA6 2JR, UK
SOURCE: Journal of Medicinal Chemistry (1991), 34(7), 2268-74
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 115:49507
GI



I



II

AB Several novel title compds. e.g., I (R = H, n = 3, 5, 9; R = Ac, n = 3) and II (R = H, MeO) having both a 2-nitroimidazole nucleus and a fluorescent ring system in their mol. structure were prepd. and evaluated as potential fluorescent probes for hypoxia. Bioredn. of nitroimidazoles, which is inhibited by oxygen, is known to lead to binding of bioreductive metabolites to cellular macromols. and this provides a mechanism for binding the fluorescent moiety to hypoxic cells. These compds. can incorporate a wide range of fluorophors and can therefore be designed to suit the laser-line wavelengths available for excitation of fluorescence in the flow cytometer. Several nitroimidazoles with naphthalimide side chains were rapidly taken up into cells and became concd. in the cells, thus reducing their concn. in the extracellular medium. This suggests a potential microscopic bioavailability problem with probes of this type when used in vivo as they would become progressively depleted in the extracellular fluid as they diffused from blood vessels, through layers of packed cells in tumors, to the hypoxic cells where they could undergo hypoxia-specific metab.

L11 ANSWER 29 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 2-A

L11 ANSWER 29 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)

IT **133932-19-1P 133932-28-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as fluorescent marker for hypoxic cells)
RN 133932-19-1 CAPLUS
CN 2H-1-Benzopyran-3-carboxamide, N-[2-[(2-hydroxyethyl)[2-hydroxy-3-(2-nitro-1H-imidazol-1-yl)propyl]amino]ethyl]-7-methoxy-2-oxo- (9CI) (CA INDEX NAME)



RN 133932-28-2 CAPLUS
CN 2H-1-Benzopyran-2-one, 4-[[[2-[[2-hydroxy-3-(2-nitro-1H-imidazol-1-yl)propyl]amino]ethyl]thio]methyl]-7-methoxy- (9CI) (CA INDEX NAME)

PAGE 1-A



L11 ANSWER 30 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1991:207838 CAPLUS
DOCUMENT NUMBER: 114:207838
TITLE: Preparation of (aminothioacyl)benzimidazolones as thioacylating reagents and intermediates for the preparation of thiopeptides
INVENTOR(S): Brillon, Denis; Sauve, Gilles; Boulos, Zacharie; Di Belleau, Bernard
PATENT ASSIGNEE(S): IAF Biochem International Inc., Can.
SOURCE: PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9101976	A1	19910221	WO 1990-CA248	19900803
W: AT, AU, BG, BR, CA, CH, DE, DK, ES, FI, GB, HU, JP, KP, KR, LU, NL, NO, RO, SD, SE, SU				
RW: AT, BE, BF, BJ, CF, CG, CH, CM, DE, DK, ES, FR, GA, GB, IT, LU, ML, MR, NL, SE, SN, TD, TG				
US 5138061	A	19920811	US 1989-389852	19890804
CA 2059647	AA	19910205	CA 1990-2059647	19900803
CA 2059647	C	20010605		
AU 9060642	A1	19910311	AU 1990-60642	19900803
AU 651557	B2	19940728		
EP 485458	A1	19920520	EP 1990-911857	19900803
EP 485458	B1	19971022		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
JP 05501865	T2	19930408	JP 1990-510785	19900803
JP 3165698	B2	20010514		
HU 63395	A2	19930830	HU 1992-338	19900803
AT 159521	E	19971115	AT 1990-911857	19900803
ES 2109236	T3	19980116	ES 1990-911857	19900803

PRIORITY APPLN. INFO.: US 1989-389852 A 19890804
WO 1990-CA248 A 19900803
OTHER SOURCE(S): CASREACT 114:207838; MARPAT 114:207838
GI



I

AB (Aminothioacyl)benzimidazolones I [R1 = (protected) amino acid side chain; R2 = amino protecting group; R3 = H, Me, Et, R1R3 = (CH2)n, n = 2-4; R4 =

H, R1R4 = (CH2)m, m = 1-5; R5 = H, halogen, amido, amino, guanidino, CO2H,
CO2Me, CN, OH, CH2OH, SH, NO2] are prepd. as thioacylating agents, intermediates in the prepn. of thiopeptides. Thus, condensation of 1,2-(HZN)2C6H4 with Boc-Ser(CH2Ph)-OH (Boc = Me3CO2C) gave aminoanilide
Boc-Ser(CH2Ph)-NHC6H4NH2-2 (II) in 97% yield. Sulfuration of II with P2S5
gave thioamide Boc-L-NHCH(CH2OCH2Ph)CSNHC6H4NH2-2 (III) in 50% yield. Cyclocondensation of III with carbonyl ditriazole gave L-I (R1 = CH2OCH2Ph, R2 = Boc, R3-R5 = H) in 91% yield. Several I underwent soln.
and solid-phase peptide coupling reactions to give thioamide analogs of
tuftsin and thymopentin. The immunomodulatory activity of 4-thiothymopentin on T cell development showed 128-227% increase over control animals.

IT **133704-10-6P 133704-14-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 133704-10-6 CAPLUS
CN Carbamic acid, [1-[(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)thioxomethyl]-3-oxo-3-(9H-xanthen-9-ylamino)propyl]-, 1,1-dimethylethyl ester, (S)-(9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 133704-14-0 CAPLUS
CN Carbamic acid, [1-[(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)thioxomethyl]-4-oxo-4-(9H-xanthen-9-ylamino)butyl]-, 1,1-dimethylethyl ester, (S)-(9CI)
(CA INDEX NAME)

Absolute stereochemistry.



ACCESSION NUMBER: 1990:497313 CAPLUS
DOCUMENT NUMBER: 113:97313
TITLE: Reactions of 3-formylvisnagin and 3-formylkhellin with 2-thiohydantoin derivatives
AUTHOR(S): Abdelaziz, Mahfouz A.; Hishmat, O. H.; El-Naem, S. I.; Fawzy, N. M.
CORPORATE SOURCE: Fac. Sci., Cairo Univ., Giza, Egypt
SOURCE: Sulfur Letters (1990), 10(6), 255-67
CODEN: SULED2; ISSN: 0278-6117
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 113:97313
GI



AB 3-Formylvisnagin and 3-formylkhellin condensed with the 2-thiohydantoin derivs. to afford the 4-arylidene-2-thiohydantoins I (R = H, OMe; R1, R2 = H, Ph; X = S. When I (X = S) were fused with primary arom. amines the 2-arylimino derivs. I (X = NPh, NC6H4Me-4) were obtained. I (R = H, OMe; R1 = H, Ph; R2 = H; X = S) have been condensed with CH2O and PhNH2 to give I (R2 = CH2NHPh). Treatment of I (R = H, OMe, R1 = R2 = H, X = S) with ClCH2CO2H gave the corresponding acids which on cyclization with AC2O gave the imidazothiazole derivs. II.

IT **128838-64-2P 128838-65-3P 128838-66-4P 128838-67-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 128838-64-2 CAPLUS
CN 4-Imidazolidinone, 5-[(4-methoxy-5-oxo-5H-furo[3,2-g][1]benzopyran-6-yl)methylene]-3-[(phenylamino)methyl]-2-thioxo- (9CI) (CA INDEX NAME)



RN 128838-65-3 CAPLUS
CN 4-Imidazolidinone, 5-[(4-methoxy-5-oxo-5H-furo[3,2-g][1]benzopyran-6-yl)methylene]-1-phenyl-3-[(phenylamino)methyl]-2-thioxo- (9CI) (CA INDEX NAME)



RN 128838-66-4 CAPLUS
CN 4-Imidazolidinone, 5-[(4,9-dimethoxy-5-oxo-5H-furo[3,2-g][1]benzopyran-6-yl)methylene]-3-[(phenylamino)methyl]-2-thioxo- (9CI) (CA INDEX NAME)

L11 ANSWER 31 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 128838-67-5 CAPLUS
CN 4-Imidazolidinone,
5-[(4,9-dimethoxy-5-oxo-5H-furo[3,2-g][1]benzopyran-6-yl)methylene]-1-phenyl-3-[(phenylamino)methyl]-2-thioxo- (9CI) (CA INDEX NAME)



L11 ANSWER 32 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1990:7422 CAPLUS
DOCUMENT NUMBER: 112:7422
TITLE: New synthesis of chromonopyrroloimidazolinones and arylidenethioxoimidazolinones. Study of their antimicrobial activities
AUTHOR(S): Aziz, Mahfouz A. Abdel; Riad, Bahia Y.; Shalaby, A. M.
CORPORATE SOURCE: Fac. Sci., Cairo Univ., Giza, Egypt
SOURCE: Archives of Pharmacal Research (1989), 12(1), 12-16
CODEN: APHRDQ; ISSN: 0253-6269
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB 6-Formyl-5-methoxy-2-methylchromone derivs. I (R = H, NO2, Br, R1 = OH; R = H, R1 = OMe) condensed with 2-thioxo-4-imidazolinones II (R2 = H, R3 = H, Ph; R2 = Ph, R3 = H) to form the corresponding chromonopyrroloimidazolinones III or the arylidenethioxoimidazolinones IV. The activity of the imidazole moiety NH of III (R = R3 = H) (V) was confirmed by formation of the Mannich bases. Moreover, alkylation of V was gave alkylmercapto derivs. The antimicrobial activities of compds. II

L11 ANSWER 32 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)
and IV were studied.
IT **124041-49-2P 124041-50-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 124041-49-2 CAPLUS
CN 4H,7H-Imidazo[1,5-a]pyrano[3,2-f]indole-4,7-dione, 8,9-dihydro-5-methoxy-2-methyl-8-[(phenylamino)methyl]-9-thioxo- (9CI) (CA INDEX NAME)



RN 124041-50-5 CAPLUS
CN 4H,7H-Imidazo[1,5-a]pyrano[3,2-f]indole-4,7-dione, 8,9-dihydro-5-methoxy-2-methyl-8-[[(4-methylphenyl)amino]methyl]-9-thioxo- (9CI) (CA INDEX NAME)



L11 ANSWER 33 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1983:416554 CAPLUS
DOCUMENT NUMBER: 99:16554
TITLE: Enzyme immunoassay of theophylline
PATENT ASSIGNEE(S): Miles Laboratories, Inc., USA
SOURCE: Jpn. Kokai Tokkyo Koho, 17 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 58046072	A2	19830317	JP 1982-146984	19820826
JP 02031825	B4	19900717		
US 4533493	A	19850806	US 1981-296817	19810827
CA 1210757	A1	19860902	CA 1982-406303	19820629
EP 77896	A1	19830504	EP 1982-107414	19820816
EP 77896	B1	19890125		
R: DE, FR, GB				
US 4460772	A	19840717	US 1983-493632	19830511
US 4608336	A	19860826	US 1983-493609	19830511

PRIORITY APPLN. INFO.: US 1981-296817 19810827
OTHER SOURCE(S): CASREACT 99:16554
GI



AB Theophylline (I) [58-55-9] is detd. in blood by immunochem. methods. I-antigens were prepd. for the prepn. of antibodies. For example, 9-(5-carboxypentyl)-1,3-dimethylxanthine (II) [86227-48-7] was synthesized and then bound to bovine serum albumin to form an antigen. Procedures for the enzyme immunochem. detn. of I are described.
IT **86227-51-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, in enzyme immunoassay of theophylline)
RN 86227-51-2 CAPLUS
CN 2H-1-Benzopyran-3-carboxamide, 7-(.beta.-D-galactopyranosyloxy)-2-oxo-N-[5-(1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxo-9H-purin-9-yl)pentyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 33 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)



L11 ANSWER 34 OF 42 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1983:160720 CAPLUS
DOCUMENT NUMBER: 98:160720
TITLE: Diphenylhydantoin derivatives
INVENTOR(S): Buckler, Robert T.
PATENT ASSIGNEE(S): Miles Laboratories, Inc. , USA
SOURCE: Can., 37 pp. Division of Can. Appl. No. 324,409.
CODEN: CAXXA4
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 1137987	A2	19821221	CA 1982-393745	19820107
US 4182856	A	19800108	US 1978-899844	19780425
CA 1121810	A1	19820413	CA 1979-324409	19790329

PRIORITY APPLN. INFO.: US 1978-899844 19780425
CA 1979-324409 19790329

GI



I

AB Diphenylhydantoins I (R = amino, CO2H; n = 2-6) were prepd. as intermediates in the prepn. of reagents for detecting diphenylhydantoin and its salts in biol. fluids by binding assays. Thus, 3-carbethoxy-5,5-diphenylhydantoin was treated with N-(4-bromobutyl)phthalimide to give I (R = phthalimido, n = 4). Hydrazinolysis of the latter gave I (R = NH2 n = 4).

IT **73304-25-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, for diphenylhydantoin detn.)

RN 73304-25-3 CAPLUS
CN 2H-1-Benzopyran-3-carboxamide, N-[4-(2,4-dioxo-5,5-diphenyl-1-imidazolidinyl)butyl]-7-(.beta.-D-galactopyranosyloxy)-2-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 34 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)



L11 ANSWER 35 OF 42 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1983:160717 CAPLUS
DOCUMENT NUMBER: 98:160717
TITLE: Diphenylhydantoin derivatives
INVENTOR(S): Buckler, Robert T.
PATENT ASSIGNEE(S): Miles Laboratories, Inc. , USA
SOURCE: Can., 37 pp. Division of Can. Appl. No. 324,409.
CODEN: CAXXA4
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 1137988	A2	19821221	CA 1982-393746	19820107
US 4182856	A	19800108	US 1978-899844	19780425
CA 1121810	A1	19820413	CA 1979-324409	19790329

PRIORITY APPLN. INFO.: US 1978-899844 19780425
CA 1979-324409 19790329

GI



I

AB Hydantoins I (R = amino, CO2H; n = 2-6) were prepd. as intermediates in the prepn. of reagents for detecting diphenylhydantoin and its salts in biol. fluids by binding assays. Thus, 2-HOC6H4COPh was treated with N-(4-bromobutyl)phthalimide to give 2-(4-phthalimidobutoxy)benzophenone. This was cyclized with KCN and (NH4)2CO3 to give I (R = NHCHO, n = 4), which was hydrolyzed to give I (R = NH2, n = 4).

IT **73304-25-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, for diphenylhydantoin detn.)

RN 73304-25-3 CAPLUS
CN 2H-1-Benzopyran-3-carboxamide, N-[4-(2,4-dioxo-5,5-diphenyl-1-imidazolidinyl)butyl]-7-(.beta.-D-galactopyranosyloxy)-2-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 35 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)



L11 ANSWER 36 OF 42 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1983:50007 CAPLUS
DOCUMENT NUMBER: 98:50007
TITLE: Reagents and method of immunodetermination by fluorescence polarization using carboxyfluorescein
INVENTOR(S): Wang, Chao Huei Jeffrey; Stroupe, Stephen; Jolley, Michael Ernest
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: Belg., 37 pp.
CODEN: BEXXAL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
BE 892158	A1	19820816	BE 1982-207329	19820216
AU 8280328	A1	19820826	AU 1982-80328	19820210
AU 555213	B2	19860918		
GB 2111476	A1	19830706	GB 1982-3971	19820211
GB 2111476	B2	19850403		
FR 2500165	A1	19820820	FR 1982-2502	19820216
FR 2500165	B1	19850614		
JP 57150680	A2	19820917	JP 1982-22907	19820217
JP 01023061	B4	19890428		
US 5066426	A	19911119	US 1984-644172	19840823
PRIORITY APPLN. INFO.:			US 1981-235259	19810217
			US 1981-329974	19811211
			US 1982-443401	19821122

AB An immunol. method and reagents are described for the detn. of ligands in, e.g., body fluids by using fluorescence polarization and a tracer composed of carboxyfluorescein (I) and an analog of the ligand (e.g., a drug, metabolite, hormone, or their derivs.) with a primary or secondary amino group. A sample was incubated with the I tracer, a surfactant, and an antibody specific for the ligand and for the tracer, and the amt. of bound tracer was measured by fluorescence polarization. Thus, for the detn. of phenytoin in blood serum, a .beta.-aminoethyl-2-phenytoin-1 tracer was prepd. and mixed in a tube with sample dild. with Na phosphate buffer (pH 7.5) contg. .gamma.-globulin and NaN3. Antiserum was added, followed by incubation at room temp. for 15 min and measurement of fluorescence polarization, which decreased with increasing concns. of phenytoin.

IT **84140-86-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, for fluorescence-polarization immunoassay)

RN 84140-86-3 CAPLUS

CN Spiro[isobenzofuran-1(3H),9'-[9H]xanthene]-ar-carboxamide, N-[2-(2,5-dioxo-4,4-diphenyl-1-imidazolidinyl)ethyl]-3',6'-dihydroxy-3-oxo- (9CI) (CA INDEX NAME)

L11 ANSWER 36 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)



L11 ANSWER 37 OF 42 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1980:174695 CAPLUS
DOCUMENT NUMBER: 92:174695
TITLE: Reagents for use in binding samples in the detection of diphenylhydantoin
INVENTOR(S): Buckler, Robert Thomas
PATENT ASSIGNEE(S): Miles Laboratories, Inc., USA
SOURCE: Ger. Offen., 43 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2914842	A1	19791031	DE 1979-2914842	19790411
DE 2914842	C2	19831117		
US 4182856	A	19800108	US 1978-899844	19780425
PRIORITY APPLN. INFO.:			US 1978-899844	19780425

GI



AB Reagents for detection of diphenylhydantoin (I) [57-41-0] and its salts in biol. fluids, by binding assays, are described. These reagents include labeled I conjugates II (R = PhO and diphenylhydantoinyl; n = 2-6) directly used, and immunogens for prepg. I-specific antibodies. The labeled conjugates were prepd. by the reaction of a mixed anhydride (from .beta.-galactosylumbelliferone-3-carboxylate and an alkyl chloroformate) with either N1- or N3-(.omega.-aminoalkyl)diphenylhydantoin, or [o-(.omega.-aminoalkoxy)phenyl]phenylhydantoin. The immunogen conjugates were prepd. by the reaction of N1- or N3-(.omega.-carboxyalkyl)diphenylhydantoin, or [o-(.omega.-carboxyalkoxy)phenyl]phenylhydantoin with a polyamino acid such as albumin under conditions favorable to the formation of amide linkage. The usefulness of these reagents was demonstrated.

IT **73304-25-3P 73461-84-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, for diphenylhydantoin detn.)

RN 73304-25-3 CAPLUS

L11 ANSWER 37 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN 2H-1-Benzopyran-3-carboxamide, N-[4-(2,4-dioxo-5,5-diphenyl-1-imidazolidinyl)butyl]-7-(.beta.-D-galactopyranosyloxy)-2-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 73461-84-4 CAPLUS
CN 2H-1-Benzopyran-3-carboxamide, N-[4-(2,5-dioxo-4,4-diphenyl-1-imidazolidinyl)butyl]-7-(.beta.-D-galactopyranosyloxy)-2-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L11 ANSWER 38 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1980:157931 CAPLUS
DOCUMENT NUMBER: 92:157931
TITLE: Reagents for use in binding assays to determine diphenylhydantoin
INVENTOR(S): Buckler, Robert T.
PATENT ASSIGNEE(S): Miles Laboratories, Inc., USA
SOURCE: U.S., 11 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4182856	A	19800108	US 1978-899844	19780425
US 4194048	A	19800318	US 1978-967131	19781207
US 4213894	A	19800722	US 1978-967132	19781207
US 4213964	A	19800722	US 1978-967136	19781207
CA 1121810	A1	19820413	CA 1979-324409	19790329
DE 2914842	A1	19791031	DE 1979-2914842	19790411
DE 2914842	C2	19831117		
GB 2021564	A	19791205	GB 1979-13979	19790423
GB 2021564	B2	19820804		
GB 2038838	A	19800730	GB 1980-1180	19790423
GB 2038838	B2	19820811		
GB 2039485	A	19800813	GB 1979-1179	19790423
GB 2039485	B2	19821020		
GB 2039484	A	19800813	GB 1980-1178	19790423
GB 2039484	B2	19821020		
CA 1137987	A2	19821221	CA 1982-393745	19820107
CA 1137988	A2	19821221	CA 1982-393746	19820107
CA 1142511	A2	19830308	CA 1982-393747	19820107
CA 1142512	A2	19830308	CA 1982-393748	19820107
PRIORITY APPLN. INFO.:			US 1978-899844	19780425
			CA 1979-324409	19790329

GI

I

AB Reagents for detection of diphenylhydantoin (I) [57-41-0] and its salts in biol. fluids, by binding assays, are described. They include labeled I conjugates directly used, and immunogen for prepg. I-specific antibodies.
The labeled conjugates were prepd. by the reaction of a mixed anhydride

L11 ANSWER 38 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)
(from .beta.-galactosylumbelliferone-3-carboxylate and an alkyl chloroformate) with either N1- or N3-(.omega.-aminoalkyl)diphenylhydantoins, or [o-(.omega.-aminoalkoxy)phenyl]phenylhydantoins. The immunogen conjugates were prepd.
by the reaction of N1- or N3-(.omega.-carboxyalkyl)diphenylhydantoins, or [o-(.omega.-carboxyalkoxy)phenyl]phenylhydantoins with a polyaminoacid
such an albumin under conditions favorable to the formation of amide linkages. The usefulness of these reagents was demonstrated.
IT **73304-25-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, for diphenylhydantoin detn.)
RN 73304-25-3 CAPLUS
CN 2H-1-Benzopyran-3-carboxamide, N-[4-(2,4-dioxo-5,5-diphenyl-1-imidazolidinyl)butyl]-7-(.beta.-D-galactopyranosyloxy)-2-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L11 ANSWER 39 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1979:160117 CAPLUS
DOCUMENT NUMBER: 90:160117
TITLE: Silver halide color photographic yellow couplers
INVENTOR(S): Kawakatsu, Tetsu; Yamashita, Kiyoshi
PATENT ASSIGNEE(S): Mitsubishi Paper Mills, Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 53139534	A2	19781205	JP 1977-53671	19770512
JP 56007220	B4	19810217		
PRIORITY APPLN. INFO.:			JP 1977-53671	19770512

GI



I



II

AB Compds. of the general formula I (R, R1, R2 = H, alkyl, aralkyl, aryl; R3 = H, or a group released during color development; R4 = halo, alkyl, alkoxy; the imidazolidinedionyl group is attached to 4- or 5-position of the benzene ring) are used as Ag halide color photog. yellow couplers. The couplers exhibit good dispersion stability (i.e. do not form ppts., etc.) and yield dye images having good light-fastness. Thus, the yellow coupler II 4 .times. 10-8 mol was added to a Ag(Br,Cl) emulsion [AgCl 25 mol%; 20 g gelatin, 8 .times. 10-3 mol Ag(Br,Cl)] 400 g by using a conventional method and the emulsion was coated on a polyester film support to give a photog. film. The film was sensitometrically exposed and developed to give Dmax of 2.30.

L11 ANSWER 39 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)
IT **69963-86-6 69963-87-7**
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. yellow coupler)
RN 69963-86-6 CAPLUS
CN Pentanamide, N-[2-chloro-5-[3-(2-ethylhexyl)-2,5-dioxo-1-imidazolidinyl]phenyl]-4,4-dimethyl-3-oxo-2-[(2-oxo-2H-1-benzopyran-4-yl)oxy]- (9CI) (CA INDEX NAME)



RN 69963-87-7 CAPLUS
CN Pentanamide, N-[2-chloro-5-(3-dodecyl-2,5-dioxo-1-imidazolidinyl)phenyl]-4,4-dimethyl-3-oxo-2-[(2-oxo-2H-1-benzopyran-4-yl)oxy]- (9CI) (CA INDEX NAME)

L11 ANSWER 39 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)



IT **69963-94-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 69963-94-6 CAPLUS
CN Pentanamide, N-[5-(4-butyl-3-octadecyl-2,5-dioxo-1-imidazolidinyl)-2-chlorophenyl]-4,4-dimethyl-3-oxo-2-[(2-oxo-2H-1-benzopyran-4-yl)oxy]- (9CI) (CA INDEX NAME)



L11 ANSWER 40 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1977:464878 CAPLUS
DOCUMENT NUMBER: 87:64878
TITLE: Addition of a fluorescent label to the 3'-hydroxyl terminal of DNA and to the 3'-hydroxyl terminal of the nascent RNA chain
AUTHOR(S): Rosovskaya, T. A.; Bibilashvili, R. Sh.; Tarusova, N. B.; Gurskii, G. V.; Strel'tsov, S. A.
CORPORATE SOURCE: Inst. Mol. Biol., Moscow, USSR
SOURCE: Molekulyarnaya Biologiya (Moscow) (1977), 11(3), 598-610
CODEN: MOBIBO; ISSN: 0026-8984
DOCUMENT TYPE: Journal
LANGUAGE: Russian
AB Fluoresceinylisothiocyanate, Na salt, was reacted with glycylglycine to form fluoresceinylaminothiocarbonylglycylglycine, which was converted to the Me ester with MeN2. With the aid of carbonyldiimidazole, this compd. was linked to UTP to form 3'(2')-O-fluoresceinylaminothiocarbonylglycylgly cyluridine-5-triphosphate (I). In some expts., 3H-labeled glycine was inserted between the 2 glycyl residues of I with the aid of carbonyldiimidazole. Rhodamine C was linked to UTP via carbonyldiimidazole to form 3'(2')-O-rhodaminyluridine-5'-triphosphate. Calf thymus deoxyribonucleotide transferase was able to link irreversibly these UTP derivs. to the 3' end of DNA. They could also be linked to the growing RNA, on the 3' end, by Escherichia coli DNA-dependent RNA polymerase, although some inhibition of RNA synthesis occurred.
IT **64060-93-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of, with UTP, DNA and RNA fluorescent labeling in relation to)
RN 64060-93-1 CAPLUS
CN Acetamide, 2-[[[(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-5-yl)amino]thioxomethyl]amino]-N-[2-(1H-imidazol-1-yl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

L11 ANSWER 40 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)



L11 ANSWER 41 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1976:421371 CAPLUS
DOCUMENT NUMBER: 85:21371
TITLE: N-(Heterocyclic-alkyl)-9-xanthenylamines
INVENTOR(S): Bender, Paul E.; Loev, Bernard; Perchonock, Carl D.
PATENT ASSIGNEE(S): Smithkline Corp., USA
SOURCE: U.S., 6 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3949076	A	19760406	US 1975-582055	19750529

PRIORITY APPLN. INFO.: US 1975-582055 19750529
GI



I

AB Seven xanthenylamines I [R = H, Cl; R1 = H, Me, Et; R2 = imidazolylalkyl, imidazolinylalkyl, or 2-(1,4,5,6-tetrahydro-1-pyrimidinyl)ethyl; R3 = H, OMe], useful as gastric acid secretion inhibitors and for treatment of gastric and duodenal ulcers as indicated by tests in rats and monkeys, were prepd. by reaction of 9-acetoxyxanthenes with HNR1R2. Thus, xanthydrol was treated with MeNCO in the presence of Et3N and the product stirred with AcOH in ether to give 9-acetoxyxanthene, which was heated with 1-(2-aminoethyl)imidazole in C6H6 at reflux to give I [R = R1 = R3 = H; R2 = 2-(1-imidazolyl)ethyl].

IT **59543-83-8P 59543-86-1P 59543-88-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, for use as gastric acid secretion inhibitor)

RN 59543-83-8 CAPLUS
CN 1H-Imidazole-1-propanamine, N,.alpha.-dimethyl-N-9H-xanthen-9-yl- (9CI)
(CA INDEX NAME)

L11 ANSWER 41 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)



L11 ANSWER 41 OF 42 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 59543-86-1 CAPLUS
CN 1H-Imidazole-1-ethanamine, 4,5-dihydro-N,.alpha.,2-trimethyl-N-9H-xanthen-9-yl- (9CI) (CA INDEX NAME)



RN 59543-88-3 CAPLUS
CN 1H-Imidazole-1-propanamine, N-ethyl-.alpha.-methyl-N-9H-xanthen-9-yl- (9CI) (CA INDEX NAME)

L11 ANSWER 42 OF 42 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1960:39142 CAPLUS
DOCUMENT NUMBER: 54:39142
ORIGINAL REFERENCE NO.: 54:7739e-g
TITLE: Nitrogen-substituted 2-chromonecarboxamides
INVENTOR(S): Kohlstaedt, Erwin; Klingler, Karl H.; Genauck, Wolfgang
PATENT ASSIGNEE(S): Chemiewerk Homburg Akt.-Ges.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 970224		19580818	DE	

AB Schiff bases from 2-chromonecarboxylates and primary amines or mixts. thereof with substituted 2-chromonecarboxamides were treated with mineral acids in the presence of H2O or org. solvents to give the title compds., useful as pharmaceuticals. Thus, PrNH2 12 was added portionwise with shaking to a cool mixt. of Bu 2-chromone carboxylate 5.6 and abs. EtOH 40 parts, the mixt. kept at room temp. 48 hrs. with exclusion of air, then ice H2O added slowly to give 4-propylimino-2-chromonecarboxylic acid propylamide, m. 99-100.degree., which treated with boiling 12% aq. HCl gave 2-chromonecarboxylic acid propylamide, m. 166.degree.. Similarly were prepd. the following 2-chromonecarboxylic acid substituted amides (substituent and m.p. given): Bu, 136-7.degree.; PhCH2, 176-8.degree.; furfuryl, 183-4.degree.; .beta.-(7-theophyllinyl)ethyl, 286.degree.. Similarly was prepd. 7-methoxy-2-chromonecarboxylic acid benzylamide, m. 165-7.degree..

IT **109694-00-0**, 4H-1-Benzopyran-2-carboxamide, 4-oxo-N-[2-(1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxopurin-7-yl)ethyl]-
(prepn. of)

RN 109694-00-0 CAPLUS
CN 4H-1-Benzopyran-2-carboxamide, 4-oxo-N-[2-(1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxopurin-7-yl)ethyl]- (6CI) (CA INDEX NAME)



```
=> fil stnguide
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    190.93     717.79

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -27.34     -27.34

FILE 'STNGUIDE' ENTERED AT 12:56:11 ON 02 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Mar 31, 2003 (20030331/UP).

=>

---Logging off of STN---


=>
Executing the logoff script...


=> LOG Y

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                      1.08     718.87

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                      0.00     -27.34

STN INTERNATIONAL LOGOFF AT 13:06:41 ON 02 APR 2003
```